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Epstein-Barr Virus (EBV) is a B cell transforming virus that causes B cell malignancies 
under conditions of immune suppression. EBV orchestrates B cell transformation through 
its Latent Membrane Proteins (LMPs) and Epstein Barr Nuclear Antigens (EBNAs). We 
here identify secondary mutations in mouse B cell lymphomas induced by LMP1, to 
predict and identify key-functions of other EBV genes during transformation. We find 
aberrant activation of Early B Cell Factor 1 (EBF1) to promote transformation of LMP1-
expressing B cells by inhibiting their differentiation to plasma cells. EBV EBNA3A 
phenocopies EBF1-activies in LMP1 expressing B cells, promoting transformation while 
inhibiting differentiation. In cells expressing LMP1 together with LMP2A, EBNA3A only 
promotes lymphomagenesis when the EBNA2-target Myc is also overexpressed. 
Collectively, our data support a model where pro-proliferative activities of LMP1, LMP2A 
and EBNA2 in combination with EBNA3A-mediated inhibition of terminal plasma cell 
differentiation critically control EBV-mediated B cell lymphomagenesis. 
Significance statement 
 
Epstein-Barr Virus (EBV) efficiently transforms human B cells and causes B cell 
lymphomagenesis especially in immunocompromised patients. We study this process in 
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genetically engineered mice to untangle the interplay of EBV oncogenes. We find Epstein 
Barr Nuclear Antigen (EBNA) 3A to have both oncogenic and tumor suppressive roles. 
First, EBNA3A promotes B cell transformation by inhibiting LMP-driven plasma cell 
differentiation, a function which can be mimicked by aberrant activation of Early B cell 
factor 1 (EBF1). Second, EBNA3A blunts Myc-driven proliferation, rendering B cell 
transformation dependent on Myc activation by the EBV protein EBNA2. The presented 
mouse model thus highlights the role of EBV oncogenes in orchestrating B cell 
transformation through control of B cell differentiation and MYC levels. 
 
Introduction  
Epstein Barr Virus (EBV) is a B-lymphotropic g-herpesvirus that is endemic in humans, 
with more than 90% of the population latently infected (1). EBV is the only known virus 
capable to in vitro transform human B cells into continuously proliferating lymphoblastoid 
cell lines (LCLs). In healthy individuals proliferating EBV-infected B cells are eliminated 
by a T and NK cell mediated immune response, restricting infection to rare memory B 
cells with no or limited viral gene expression (2). Immunocompromised patients fail to 
control infected B cells and are thus prone to develop EBV+ B cell pathologies (2). A 
prominent example are EBV+ post-transplant lymphoproliferative disorders (PTLDs) 
arising in up to 22% of patients undergoing immunosuppressive drug treatment after 
organ transplantation (3). EBV+ PTLDs present as polymorphic or monomorphic disease, 
the latter mostly resembling Activated B Cell-Like (ABC)-DLBCL and less frequently, 
Hodgkin- (HL) or Burkitt-lymphoma (BL) or plasma cell neoplasms (3). PT-ABC-DLBCLs 
usually express the EBV growth program (called latency III) which also facilitates B cell 
to LCL transformation in vitro, suggesting that EBV is the main driving force in such 
tumors (1, 4). The EBV growth program involves expression of several non-coding RNAs, 
three Latent Membrane Proteins (LMPs) and seven Epstein Barr Nuclear Antigens 
(EBNAs) (1). LMPs and EBNAs were shown to control key steps of B cell activation: LMP1 
mimics an active CD40 receptor to mainly induce NF-kB and JNK signaling pathways (5, 
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6). LMP2A resembles a constitutively active B cell receptor (BCR), primarily activating 
PI3K and MAPK signaling (7–9). EBNA2 mimics NOTCH in binding to RBP-J and 
activating target genes, most notably MYC (10). EBNA3A and 3C also bind RBP-J but 
serve as transcriptional repressors, epigenetically silencing the tumor suppressor genes 
CDKN2A (p16-INK4a/ARF) and BCL2L11 (BIM) (11). Despite ample work on the activity 
of LMPs and EBNAs during in vitro transformation, their impact on B cell 
lymphomagenesis in vivo remains elusive. This is largely due to EBV not infecting small 
laboratory animals (12). Furthermore, modeling EBV-pathologies in transgenic mice had 
a limited success, with only LMP1-transgenic mice showing reliable B cell tumor 
development at old age (8, 13–18). More recently, EBV-infection in mice reconstituted 
with human hematopoietic cells is successfully used to recapitulate virally-driven B cell 
lymphomagenesis (19), yet this approach like the transformation of human B cells in vitro 
relies on infectious EBV, making it challenging to study the activity of single LMP or EBNA 
genes. 
We previously developed a conditional transgenic mouse model that recapitulates EBV-
driven lymphomagenesis in immunodeficient hosts (20). In this model, B cell specific 
activation of a Rosa26 (R26) LMP1-transgene induces B cell proliferation followed by 
their T cell-mediated elimination. In T cell-deficient mice LMP1-expressing B cells (LMP1 
B cells) cause a lymphoproliferative disease (LPD) that within few months spontaneously 
progresses to lymphoma. Strikingly, such LMP1-driven lymphomas (LMP1-Ls) are 
monoclonal, arguing that spontaneous somatic mutations are required to transform LMP1 
B cells. We set out to identify such mutations in order to define pathways that must be 
engaged by EBV for successful B cell transformation. A recurrent activating mutation of 
the B cell transcription factor EBF1 turned out to be a functional proxy of the EBV gene 
EBNA3A in its interplay with other EBV oncogenes in B cell transformation. 
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Results  
Ebf1 and Rel are aberrantly activated in mouse LMP1-Lymphomas  
Previously established LMP1-Ls were created on a mixed genetic background and 
without a reporter, rendering it challenging to prepare pure lymphoma samples for genetic 
analysis (20). We here combined a R26LMP1-ires-huCD2stopf allele (R26LMP1stopf) (21) 
with Cd3eKO to confer T cell deficiency and Cd19-Cre for B cell specific deletion of the 
floxed stop-cassette (stopf) to allow LMP1 and huCD2-reporter expression on a C57BL/6 
background. To create a lymphoma cohort, we transplanted fetal liver hematopoietic stem 
and progenitor cells (fHSPC) from Cd3eKO;Cd19-Cre;R26LMP1stopf mice into irradiated 
RAG2KOcgKO mice (tpLMP1 mice) (Fig. 1A). Within 7 months all tpLMP1 mice developed 
LMP1-Ls infiltrating liver, lung and spleen (Fig. 1B, S1A). In line with previous findings 
(20), histologic analyses graded LMP1-Ls as CD10-, BCL6- and MUM1+ (Fig. S1A, Table 
S1), resembling ABC-DLBCL (22). To separate LMP1-L cells from non-transformed LMP1 
B cells (tpLMP1 B cells), we transplanted 5x106 cells from tpLMP1 mice with primary 
tumors into secondary immunodeficient recipients. All secondary (2ry) LMP1-Ls were 
CD19+, expressed the LMP1 target FAS and a single immunoglobulin (Ig) isotype (Fig. 
S1B, Table S1). Southern blot analysis for Ig-heavy chain rearrangements confirmed B 
cell origin and clonality of 2ryLMP1-Ls (Fig. S1C). To define somatic driver mutations, we 
performed exome sequencing on 10 sorted 2ryLMP1-Ls. Tumors harbored between 16 
and 60 clonal mutations (Fig. S1D, Table S2). Mutations mostly altered non-coding 
regions. Mis- or nonsense mutations were rare and never involved the same protein 
coding sequence in independent tumors. As exome-sequencing did not reveal obvious 
candidates for driver mutations, we performed array-CGH to detect chromosomal 
aberrations. Besides expected copy number variations (CNV) in the Ig-loci on Chr6 (Igk) 
and Chr12 (Igh), the most common CNVs were complete or partial gains of Chr11 and 
Chr15 (Fig. S1E, Table S3). Interestingly, lymphomas 37 and 43 shared a copy number 
loss 3’ of the IgH-locus on Chr12 and a partial copy number gain of Chr11 (Fig. S1E, 
S1F), a pattern indicative of a non-balanced translocation between the respective loci 
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(23). Indeed, M-FISH analysis of LMP1-L-derived cell lines (LMP1-CL) confirmed t(11;12) 
translocations in tumors 37 and 43 (Fig. 1C, S1G, Table S4). Chimeric reads involving 
the Ig-loci in exome sequencing and subsequent Sanger-sequencing of the chimeric 
locus in primary LMP1-Ls mapped the exact translocation in tumor 43 to Ighe-exon 3 and 
intron 9 of Rnf145, 57kb upstream of the Ebf1 gene (Fig. 1D, S1H, S1I Table S5). Exome 
sequencing reads did not span the translocation site in tumor 37, but revealed a 
translocation in 2ryLMP1-L 31 involving the Igk-locus on Chr6 and Chr11 25kb upstream 
of Rel (encoding NF-kB transcription factor c-Rel) (Fig. 1D, S1H, S1I, Table S5). As 
translocation of genes into the proximity of Ig-enhancers is a common mechanism to 
activate oncogenes in B cell tumors (24), we determined Ebf1- and Rel-expression by 
RNA-sequencing of tpLMP1 B cells before and after transformation. Compared to naive 
B cells from C57BL/6 mice, non-transformed tpLMP1 B cells showed reduced expression 
of Ebf1 and Rel (Fig. 1E). In contrast, all 2ryLMP1-Ls overexpressed one of the two genes, 
with t(11;12)-translocated tumors 37 and 43 expressing elevated Ebf1-levels (Fig. 1E). 
Corresponding to the RNA-expression levels in the initial tumor, LMP1-CLs expressed 
elevated protein levels of EBF1 or c-Rel (Fig. S1J). LMP1-CL 45 highly expressed c-Rel 
and EBF1, although the initial tumor was Ebf1high/Rellow. Taken together, Ebf1 and Rel 
are recurrently activated in LMP1-Ls and were thus considered as secondary driver 
candidates. In non-supervised principle component analysis on global RNA-expression 
Ebf1- and Rel-expression formed separate tumor subgroups, further indicating that both 
genes define distinct LMP1-L subsets (Fig. 1F).  
Ebf1- or Rel-overexpression supports transformation of LMP1 B cells  
To analyze the impact of LMP1/EBF1 or LMP1/c-Rel co-expression on naïve B cells, we 
isolated CD43- B cells from R26LMP1stopf mice and induced LMP1-expression in vitro 
(iLMP1 B cells) by incubating the cells with HIV-TAT-coupled Cre-recombinase (TAT-Cre) 
(Fig. 2A). One day after TAT-Cre, iLMP1 B cells were transduced with retroviruses (RV) 
encoding GFP, Ebf1 or Rel. Control-transduced iLMP1 B cells transiently expanded for 
8-10 days (Fig. 2B). Strikingly, Ebf1- or Rel-transduced iLMP1 B cells continued to 
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expand and turned into continuously proliferating mouse lymphoblastoid cell lines (EBF1-
LCL, c-Rel-LCL) (Fig. 2B). Ebf1 or Rel expression in anti-CD40 (αCD40)/IL-4 stimulated 
control B cells did not promote proliferation. After 45 days PCR-analysis for diversity of 
VDJ-rearrangements indicated oligoclonal outgrowth of EBF1-LCLs and c-Rel-LCLs (Fig. 
S2A). Like human LCLs, these mouse LCLs aggregated in clumps and expressed the 
surface markers CD19, CD20, MHCII, Ig-light chain, ICAM and FAS (Fig.S2B, Table S6) 
(25, 26). Also similar to human LCLs, CD23 was expressed only in a subset of mouse 
LCLs. CD3e (not expressed on LCLs) was expressed at low levels on 1 out of 4 analyzed 
EBF1-LCLs. EBF1-LCLs could be grown from ~2% of single-sorted Ebf1-tranduced 
iLMP1 B cells, while c-Rel-LCLs rarely grew as single cell clones (Fig. 2C). To validate 
their malignancy, 3x105 freshly Ebf1- or Rel-transduced iLMP1 B cells were transferred 
into Rag2KOcgKO mice. Within 12-21 days all transplanted mice developed severe 
lymphoproliferative disease (Fig. 2D), with Rel- or Ebf1-expressing iLMP1 B cells 
expanding in liver and spleen (Fig. 2E-G). Analysis for VDJ-diversity did not indicate 
clonal selection in this timeframe (Fig. S2C). Indeed, transfer of as few as 1x103 Ebf1- or 
Rel-transduced iLMP1 B cells caused terminal lymphoproliferative disease within 
approximately 30 (LMP1/EBF1) or 60 days (LMP1/c-Rel) (Fig. 2D). Taken together, 
aberrant expression of Ebf1 or Rel leads to an efficient transformation of mouse LMP1 B 
cells in vivo and in vitro. To determine whether combined LMP1/EBF1 or LMP1/c-Rel 
expression also supports expansion of human B cells, we made use of a recently 
published system to transduce primary human tonsillar GCBs (27). While single 
transduction of Ebf1 or Rel had little impact on human GCBs, EBF1 and, to a minor extent 
c-Rel, indeed enhanced the expansion of LMP1-expressing GCBs (Fig. 2H).  
Rel-activation induces LMP1/NF-kB-target genes  
Rel overexpression in LMP1-Ls should elevate NF-kB target gene expression through 
increased nuclear c-Rel. Indeed, secondary Relhigh LMP1-Ls and the Rel/Igk translocated 
lymphoma 31 expressed more (mostly nuclear) c-Rel than non-transformed tpLMP1 B 
cells and Ebf1high LMP1-Ls (Figure S3A). Furthermore, in our RNA-sequencing data, a 
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set of previously described human LMP1/NF-kB target genes (26) was significantly more 
highly expressed in Relhigh 2ryLMP1-Ls compared to Ebf1high 2ryLMP1-Ls and tpLMP1 B 
cells (Fig. S3B, S3C). Among these genes were the anti-apoptotic Bcl2-family members 
Bcl2l1 (Bcl-X), Bcl2a1a and Bcl2a1d (BFL-1a/d) (Fig. S3D), which may well support B cell 
transformation. 
Ebf1 inhibits plasma cell differentiation of LMP1 B cells 
EBF1 is a transcription factor that is required to maintain B cell identity (28). During 
plasma cell (PC)-differentiation Ebf1 expression is silenced (29). As LMP1 suppressed 
Ebf1 transcription (Fig. 1E), we wondered whether LMP1 induces B cell differentiation 
towards PCs. Indeed, compared to naïve splenic B cells tpLMP1 B cells showed low 
expression of the B cell transcription factor genes Pax5, Ets1, Bcl6 and Bach2 and 
elevated transcription of the master PC transcription factor gene Prdm1 (Fig. 3A). 
Furthermore, tpLMP1 B cells expressed the PC-surface marker CD138 (Fig. 3B, 3D). In 
contrast, Ebf1high LMP1-Ls showed neither CD138 surface-staining nor elevated levels of 
Prdm1 mRNA (Fig. 3A, 3C, 3D). To test whether Ebf1-induction is sufficient to block 
LMP1-mediated PC-differentiation in vitro, we performed RNA-sequencing on retrovirally 
transduced iLMP1 B cells. Ebf1-overexpression blunted Prdm1 induction and shifted the 
global mRNA expression pattern of iLMP1 B cells from PC- to GCB-like (Fig. 3E-F). Ebf1-
overexpression also blunted plasma blast (PB)-differentiation of naïve B cells cultured on 
CD40-L and BAFF expressing feeders (40LB) (30) (Fig. S3E-F). Despite recent reports 
that c-Rel can suppress PC-differentiation (31), Rel-overexpression had little impact on 
Prdm1 expression in iLMP1 B cells and did not inhibit PB-differentiation of cytokine 
stimulated wild type B cells (Fig. 3E, S3E-F). Furthermore, Ebf1- but not Rel-
overexpression blunted PB-differentiation of iLMP1 B cells when transplanted into 
RAG2KOcgKO mice (Fig. S3G). GFP control transduced cells did not survive long enough 
after transplantation to be analyzed. Although c-Rel alone did not impact PB- 
differentiation, the majority of Relhigh LMP1-Ls showed low or no CD138 expression (Fig. 
3D), arguing that Relhigh LMP1-Ls also benefit from a loss of PC-differentiation. Taken 
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together, loss of PC-differentiation is a general feature of LMP1-driven lymphomagenesis, 
caused either by EBF1-activation or unknown events in the Relhigh cases. Importantly, 
suppression of PC-differentiation is considered to be a key event in NF-kB-driven ABC-
DLBCL development (32), suggesting that EBF1-suppressive effects on LMP1-induced 
PC-differentiation are critical for the transformation of LMP1 B cells to DLBCL-like tumors. 
EBNA3A inhibits PC-differentiation in transgenic mice  
We next set out to define EBV growth program genes whose role in transformation and 
differentiation might be mimicked by aberrant EBF1-activation. As LMP2A, unlike EBF1, 
was reported to promote PC-differentiation (33) we focused on EBNA genes. To 
determine their impact on LMP1-driven transformation we retrovirally overexpressed 
individual HA-tagged EBNAs in iLMP1 B cells. EBNA2 expression was below the 
detection limit and could therefore not be studied (Fig. S4A). All other EBNAs were readily 
detectable in the nucleus of transduced iLMP1 B cells, but only EBNA3A supported cell 
expansion (Fig. 4A, S4A). To study EBNA3A in vivo we generated a R26CAG-EBNA3A-
HA-ires-BFPstopf-allele (R26EBNA3Astopf) and a R26CAG-BFP-ires-huCD2stopf reporter-
allele (R26BFPstopf) (Fig. S4B-C). Both novel R26-alleles were combined with Cd19-
Crecre/+ (Cd19-Cre) for B cell specific transgene expression. Cd19-Cre;R26EBNA3Astopf 
and Cd19-Cre;R26BFPstopf mice expressed the BFP-reporter in the majority of 
(CD19+B220+) splenic B cells (Fig. 4B). HA-co-immunoprecipitation experiments in 
αCD40/IL-4 stimulated splenic B cells confirmed EBNA3A-protein expression in Cd19-
Cre;R26EBNA3Astopf B cells and conserved EBNA3A-binding to its core interaction 
partner RBP-J (Fig. S4D). Cd19-Cre;R26EBNA3Astopf and Cd19-Cre;R26BFPstopf mice 
had a normal life expectancy (Fig. 4C). Furthermore, EBNA3A-expression in B cells did 
not impact splenic size, cellularity and absolute B cell numbers (Fig. S4E). Cd19-Cre; 
R26EBNA3Astopf mice had a normal frequency of BFP+ pro-, pre- and immature B cells in 
the bone marrow, while the frequency of reporter+ mature B cells in the spleen was mildly 
reduced (Fig. 4D), an effect at least partially attributable to limited separation of BFP+ and 
BFP- B cells. Although their number was almost normal, EBNA3A+ splenic B cells showed 
a disturbed marginal zone B cells (MZB) and follicular B cells (FOB) surface staining, with 
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CD23lowCD21+ MZBs being absent and numbers of CD23+CD21low FOBs being reduced 
(Fig. S4F). Instead, most EBNA3A+ B cells were CD23lowCD21low. Despite these 
alterations, all EBNA3A+ cells expressed surface IgM and IgD levels similar to FOBs (Fig. 
S4F). Also, spleens of Cd19-Cre;R26EBNA3Astopf mice had a normal follicular structure 
including EBNA3A+ B cells locating to B cell follicles and the marginal zone (Fig. S4G). 
Although EBNA3A was expressed in more than 80% of mature splenic B cells, 
CD138+CD267+ PCs of Cd19-Cre;R26EBNA3Astopf mice rarely expressed EBNA3A (Fig. 
4E). Furthermore, the frequency of antibody secreting cells (ASC) among BFP+ cells in 
the bone marrow of Cd19-Cre;R26EBNA3Astopf mice was more than 7-fold reduced 
compared to Cd19-Cre;R26BFPstopf mice (Fig. 4F). To address whether EBNA3A+ B cells 
can differentiate in vitro, we cultured BFP+ FOBs from Cd19-Cre;R26EBNA3Astopf and 
Cd19-Cre;R26BFPstopf mice on 40LB feeders. While FOBs from control mice readily 
differentiated into CD138+ plasma blasts, the majority of EBNA3A+ FOBs remained 
CD138- (Fig. S4H). Importantly, αCD40/IL-4 stimulated FOBs from Cd19-
Cre;EBNA3Astopf mice expanded better than control cells, arguing that CD40-signaling in 
EBNA3A+ B cells is rather elevated than impaired (Fig. S4I). Similarly, LPS and IL-4 
stimulation did not induce PC-differentiation of EBNA3A+ FOBs (Fig. S4J). Taken 
together, EBNA3A expression in mouse B cells does not promote lymphomagenesis, has 
little impact on early B cell development, distorts differentiation of mature B cell subsets 
(at least at surface marker level) and strongly inhibits terminal PC-differentiation. 
EBNA3A inhibits PC-differentiation and supports expansion of LMP1 B cells 
To evaluate the impact of EBNA3A on proliferation and differentiation of LMP1 B cells, 
we isolated B cells from R26LMP1stopf;R26EBNA3Astopf mice and activated transgene 
expression by TAT-Cre treatment (iLMP1/EBNA3A B cells). iLMP1/EBNA3A B cells 
expanded more than iLMP1 B cells, with EBNA3A supporting cell proliferation and 
inhibiting apoptosis (Fig. 5A-C). RNA-sequencing on day 6 revealed attenuated Prdm1 
expression in iLMP1/EBNA3A B cells (Fig. 5D). This effect was independent of Ebf1, as 
EBNA3A did not restore Ebf1 expression in these cells. In human B cells CDKN2A and 
BCL2L11 are considered as EBNA3As key target genes (11). In iLMP1/EBNA3A B cells, 
11   
 
EBNA3A severely blunted LMP1-induced Cdkn2a expression, while the impact on 
Bcl2l11-levels was more modest (Fig. S5A, S5B). Yet, deleting Cdkn2a- or Bcl2l11-ORFs 
by retroviral delivery of sgRNAs into iLMP1/CAS9 B cells did not promote cell expansion 
(Fig. S5C, S5D), arguing that EBNA3A-function extends beyond the suppression of 
Cdkn2a or Bcl2l11.  
To test the impact of combined EBNA3A and LMP1 expression on B cells in vivo, we 
transplanted Cd3eKO;Cd19-Cre;R26LMP1stopf;R26EBNA3Astopf fHSPCs into irradiated 
RAG2KOcgKO mice (tpLMP1/EBNA3A). In contrast to tpLMP1 mice, tpLMP1/EBNA3A 
mice developed terminal LPD within 40 days after reconstitution (Fig. 5E). Spleens of 
tpLMP1/EBNA3A mice were dramatically enlarged and filled with LMP1+/EBNA3A+ B 
cells (Fig. 5F, 5G, S5E). Analysis of VDJ-rearrangements in splenocytes of 
tpLMP1/EBNA3A mice did not indicate clonal B cell expansion at termination (Fig. S5F). 
Compared to tpLMP1 B cells tpLMP1/EBNA3A B cells showed reduced CD138 
expression and antibody secretion (Fig. 5G, 5H, S5E). Thus, EBNA3A, like EBF1, 
facilitates polyclonal expansion of LMP1 B cells while inhibiting their differentiation to PBs, 
suggesting that EBNA3A substitutes for EBF1 during EBV-driven PTLD-development.  
 
EBF1 and REL expression in human PT-DLBCLs 
 
Given the impact of c-Rel and EBF1 on LMP1-driven B cell in the mouse model, we 
wondered whether LMP1 expression in human PT-DLBCLs positively correlates with REL 
activation, while EBF1 might be specifically upregulated in LMP1+/EBNA3A- cases. 
Alternatively, the presence of the full EBV-genome in the human disease might alleviate 
the need for REL or EBF1 activation. We therefore correlated expression of EBF1 and 
REL with EBV-infection and -latency status in a published human PT-ABC-DLBCL 
dataset (34). PT-DLBCLs datasets comparing exome-mutations and  amplifications were 
either too small to be informative (37), or did not report EBV latency II cases (38–40), 
datasets reporting unbiased translocations in PT-DLBCLs were not available. In the 
expression analysis, latency II PT-ABC-DLBCLs (LMP1/2a;EBNA1) expressed rather 
less EBF1 than latency III cases (LMP1/2a;EBNA1/LP/2/3A-C) (Figure S5G), arguing that 
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the absence of EBNA3A in latency II tumors does not commonly entail EBF1 activation. 
Furthermore, REL-levels, in line with other reports (35, 36), appeared independent of EBV 
infection (Figure S5G). Together these data suggest that the presence of the EBV 
genome alleviates the need for REL or EBF1 activation in human PT-ABC-DLBCLs. 
EBNA3A inhibits PC-differentiation of LMP1 and LMP2A expressing
 
B cells 
In the EBV growth program LMP1 and EBNA3A are co-expressed with LMP2A, which by 
itself promotes proliferation and PC-differentiation of LMP1 expressing mouse GCBs (41, 
42). To evaluate whether lymphomagenesis of GCB cells expressing both LMPs also 
requires disruption of PC-differentiation, we transferred 3x106 B cells from Cg1-Cre (GCB-
specific) R26LMP1stopf;R26LMP2Astopf mice into RAG2KO mice (Fig. 6A). Transferred cells 
contained merely 100-300 LMP1+/2A+ GCBs as these cells are continuously eliminated 
by T cells (Fig. 6B). In the reconstituted mice, LMP1+/2A+ GCBs proliferated strongly and 
overwhelmingly differentiated into CD138+CD19low PCs within 17-28 days (Fig. 6B, S6A). 
When aged, the reconstituted mice developed CD19+CD138-LMP1+/2A+ B cell 
lymphomas (Fig. 6C-E). One mouse developed a CD19+CD138-LMP1+/2A- B cell 
lymphoma (Fig. S6B). Thus, upon transfer into an immunodeficient environment, 
LMP1+/2A+ GCBs proliferate and rapidly differentiate to PCs. Yet, transformation is 
restricted to LMP1+/2A+ GCBs that do not undergo PC-differentiation.  
To allow in vivo co-expression of EBNA3A with both LMPs we generated a new 
R26LMP1t2aLMP2Astopf allele that upon deletion of the stop-cassette expresses both 
LMPs through a 2A-self cleavage peptide (Fig. S6C). Compared to the expression from 
separate R26-alleles, LMP1 expression in TAT-Cre-treated R26LMP1t2aLMP2Astopf B 
cells (iLMP1_2A B cells) was about 2-fold reduced, while LMP2A expression was 
comparable (Fig. S6D). Still, the LMP1-target FAS was induced to similar levels in 
iLMP1/2A and iLMP1_2A B cells, indicating robust NF-kB-activation under both 
conditions (Fig. S6E). iLMP1_2A B cells proliferated extensively, expressed more Prdm1 
than iLMP1 B cells and differentiated to antibody secreting CD138+/B220low PCs within 9 
days of culture (Fig. 6F, S6F, S6G). iLMP2A cells expanded little and did not differentiate 
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to PCs in their lifespan (Fig. S6H-i). In contrast to iLMP1_2A B cells, iLMP1_2A/EBNA3A 
B cells showed blunted Prdm1-expression, CD138 surface staining and antibody 
secretion (Fig. 6F, 6G, S6F). Overexpression of Prdm1 in iLMP1_2A/EBNA3A B cells 
allowed their differentiation to antibody secreting CD138+/B220low PCs (Fig. S6J-K). 
Notably, the inhibition of PC-differentiation was specific to EBNA3A as retroviral 
transduction of EBNA1, -LP, -3B and -3C failed to inhibit differentiation of iLMP1_2A B 
cells (Fig. S6L). Taken together, combined expression of LMP1 and LMP2A from a single 
allele drives proliferation and rapid PC-differentiation of B cells, which is inhibited by 
EBNA3A via Prdm1 suppression.  
Transformation of LMP1 and LMP2A expressing B cells requires 
overexpression of EBNA3A and Myc 
To test the impact of combined expression of LMP1, LMP2A and EBNA3A on B cells in 
vivo, we reconstituted RAG2KOcgKO mice with fHSPCs from Cd3εKO;Cd19-Cre; 
R26LMP1t2aLMP2Astopf (tpLMP1_2A mice) or Cd3εKO;Cd19-Cre; 
R26LMP1t2aLMP2Astopf;R26EBNA3Astopf (tpLMP1_2A/EBNA3A mice). tpLMP1_2A mice 
developed terminal LPD-symptoms within 30 to 60 days (Fig. 6H), with LMP1_2A 
expressing PCs accumulating in the spleen (Fig. S6M, S6N). Surprisingly, 
tpLMP1_2A/EBNA3A mice did not show an accelerated disease progression (Fig. 6H) 
and developed a slightly less severe splenomegaly (Fig. S6O), suggesting that EBNA3A 
does not promote expansion of LMP1_2A B cells. Indeed, a majority of splenocytes in 
tpLMP1_2A/EBNA3A mice had escaped Cre-mediated recombination of the EBNA3A-
allele and expressed only LMP1_2A (Fig. 6I). This was despite EBNA3A still suppressing 
LMP1_2A-driven PC-differentiation in the fraction of B cells that had recombined both 
alleles (Fig. 6I). To determine why EBNA3A expression is counter-selected in LMP1_2A 
B cells we compared proliferation and survival of iLMP1_2A and iLMP1_2A/EBNA3A B 
cells in vitro. Both cell types expanded at similar rates (Fig. S6P). EBNA3A inhibited 
caspase 3 activation (Fig. S6Q) but, in stark contrast to its activity in LMP1-expressing B 
cells, blunted BrdU-uptake (Fig. 7A). This suggests that EBNA3A has opposing effects 
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on proliferation and cell survival in B cells expressing both LMPs. In vitro, inhibition of 
apoptosis and proliferation appear to counterbalance each other, allowing similar 
expansion dynamics. In vivo, the reduced proliferation might outweigh anti-apoptotic 
effects and cause counter-selection of EBNA3A expressing cells. EBNA3A-
overexpression was previously reported to suppress proliferation of human LCLs by 
inhibiting MYC transcription (43). Similarly, we find iLMP1_2A/EBNA3A B cells to express 
less Myc mRNA and protein compared to iLMP1_2A B cells (Fig. 7B-C). In LMP1 B cells 
EBNA3A it did not suppress Myc (Fig. 7B, S5B). Retroviral overexpression of Myc 
promoted BrdU-uptake, cell cycle and cell expansion of iLMP1_2A/EBNA3A B cells, but 
did not elevate PC-differentiation (Fig. 7D-F, S7A-C). In iLMP1_2A B cells Myc-
overexpression had little impact on proliferation and differentiation. To determine the 
impact of Myc activation on iLMP1_2A/EBNA3A B cell transformation, we transplanted 
5x106 Myc-transduced iLMP1_2A/EBNA3A B cells into RAG2KOcgKO mice. Within 90 days 
roughly one third of transplanted mice developed LMP1_2A+, EBNA3A+ and RV-Myc+ 
lymphomas in spleen and liver (Fig. 7G, 7H). Tumors were clonal, as indicated by VDJ-
diversity restriction (Fig. S7B) and expressed CD19 but not CD138 (Fig. 7H), suggesting 
that blocked PC-differentiation is also important in such lymphomas. RAG2KOcgKO mice 
transplanted with control cells, including Myc-transduced iLMP1_2A B cells, did not 
develop lymphomas within the observation period of 150 days (Fig. 7G). Thus, aberrant 
Myc activation overrides EBNA3A suppressive effects on proliferation and together with 
EBNA3A allows transformation of LMP1_2A B cells in vivo. 
Discussion 
Here we investigate interlocking functions of EBV genes during EBV-driven B cell 
lymphomagenesis. We had previously shown that expression of LMP1 in mouse B cells 
causes spontaneous LMP1-L development in T cell deficient mice (20). We now find that 
all LMP1-Ls aberrantly activate either Ebf1 or Rel either by translocation into the Ig-locus 
or other unknown mechanisms, which possibly include the recurrent amplification of the 
Ebf1- and Rel-encoding chromosome 11. Overexpression of either gene with LMP1 in 
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mouse B cells efficiently facilitates their transformation in vitro and in vivo, arguing that 
Ebf1 and Rel are potent oncogenes in LMP1-driven B cells. The finding that LMP1/EBF1-
expressing B cells can grow out from single cells even suggests that this oncogene 
combination does not depend on additional mutations to transform at least a subset of B 
cells. Indeed, the frequency in which LMP1/EBF1 co-expression transforms single sorted 
mouse B cells in vitro (~2%) is similar to the transforming-efficiency of EBV in human B 
cells (~3-10%) (1, 44). Thus, co-expression of a single viral and a single somatic gene 
recapitulates EBV-mediated transformation of B cells in vitro and in vivo. EBF1/LMP1- 
driven B cell transformation is, to our knowledge, the first report of an efficient 2-factor B 
cell transformation, underlining the transforming potential of EBV-oncoprotein LMP1. 
Indeed, B cell transformation driven by MYC, considered to be one of the most potent 
oncogenes in B cells, still requires overexpression of at least two additional factors, like 
BCL6/BCL2 or BMI1/BCLXL or BMI1/MCL1 (27, 45). In the future mouse EBF1-LCLs 
might serve, like their human counterparts, as a simple and powerful tool for in vitro 
expansion of mature B cells, independent of exogenous cytokines or feeders. 
Given their potential to transform LMP1 B cells, we considered EBF1 and c-Rel as 
possible surrogates for EBV proteins that would cooperate with LMP1 in EBV-driven B 
cell transformation. The distinct gene expression patterns of Ebf1high and Relhigh LMP1-Ls 
might reflect different modes of viral lymphomagenesis. Importantly, EBF1 and to a minor 
extent c-REL also supported the expansion of LMP1-expressing human GCBs, indicating 
that the presented mouse model can predict genes that synergize with LMP1 in the 
transformation of human B cells.  
REL is frequently amplified in human B cell lymphomas especially GCB-DLBCLs and HL, 
suggesting an important oncogenic role (46). Yet, no direct evidence for c-Rel 
oncogenicity in a mouse B cell lymphoma model has, to our knowledge, been reported. 
On the contrary, c-Rel was shown to be a tumor suppressor in EμMyc lymphomas (47). 
We now find Rel to be a potent oncogene in mouse LMP1 B cells. Aberrant Rel-
expression likely supports LMP1-driven lymphomagenesis by promoting expression of a 
subset of proto-oncogenic NF-kB targets like Bcl-X and BFL-1, overcoming LMP1-
mediated repression of endogenous Rel. Thus, transformation of mouse B cells appears 
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to benefit from a dual activation of NF-kB. LMP1 constitutively activates the IKK signaling 
cascade, while Rel-induction ensures sufficient expression of c-Rel-sensitive oncogenic 
targets.. As REL is not specifically overexpressed in human EBV+ PT-ABC-DLBCL over 
EBV- cases and not commonly amplified in EBV+ DLBCL cases (37, 39, 40), we suspect 
that other EBV gene products substitute for REL-overexpression during the 
transformation of human B cells. Possible candidates are LMP2A and viral miRNAs which 
have been shown to modulate LMP1-driven NF-kB signaling (48, 49). If not in PTLs, the 
synergy of LMP1 and c-Rel might play out in the pathogenesis of human HLs which often 
carry REL-amplifications (~20% of cases) and express LMP1+ EBV latency II (~40% of 
cases) (50, 51). To our knowledge an analysis overlaying REL-amplification with LMP1-
expression in HL has not yet been performed.  
The recurrent activation of Ebf1 in LMP-Ls was surprising, since Ebf1 is not considered 
to be an oncogene, but has rather been described as a tumor suppressor in acute 
lymphoblastic leukemia (52, 53). Some cases of DLBCL were reported to carry mutated, 
deleted or Ig-translocated EBF1, but the impact of such mutations on tumorigenesis has 
remained elusive (38, 54–56). Interestingly, EBF1 is among 8 genes whose knockout is 
lethal in human ABC-DLBCL but not GCB-DLBCL cell lines (57), supporting the idea that 
EBF1 plays an important role specifically in ABC-DLBCLs. We find that Ebf1-
overexpression is sufficient to block cytokine- and LMP-driven PC-differentiation of 
mouse B cells. Importantly, a loss of PC-differentiation potential was previously shown to 
promote ABC-DLBCL onset in humans and mice (32, 58–60). As LMP1-Ls resemble 
ABC-DLBCLs, EBF1 likely supports transformation of LMP1 B cells through inhibition of 
terminal PC-differentiation.  
In contrast to mouse LMP1 B cells, transformation of human B cells by EBV latency III is 
not known to require additional somatic mutations (1, 61). Assuming that inhibition of 
LMP-driven PC-differentiation is indeed a critical step in the transformation of human B 
cells by EBV, one would predict that EBV itself encodes an inhibitor of PC-differentiation. 
Indeed, the EBV-gene products LMP1, miR-BHRF1-2, EBNA1 and most recently 
EBNA3A and 3C were reported to impact PC-differentiation of EBV infected human B 
cells in vitro (62–65). We now show that EBNA3A inhibits PC-differentiation and promotes 
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lymphomagenesis of mouse LMP1 B cells in vivo. (EBNA3C did, for unknown reasons, 
not affect mouse B cells). Overexpression of Prdm1 was sufficient to overcome EBNA3A 
suppressive effects on PC-differentiation in this system. Indeed, Prdm1 is a direct target 
of EBNA3A in human cells (65), supporting the idea that EBNA3A engages the same 
pathways in mouse and human cells 
As our data predicted that EBF1 can substitute for EBNA3A in LMP-driven B cell 
transformation, we wondered whether EBF1 might be selectively activated in human 
latency II (LMPs+EBNA3A-) PTLs. Yet, EBF1-expression in human PT-ABC-DLBCL was 
rather reduced in latency II over latency III cases. While this was surprising, the low case 
number in the study might be insufficient to detect rare EBF1high tumors. Note that in our 
mouse model only a subset of tumors is driven by EBF1. The low EBF1-expression in 
latency II tumors might also reflect that the progenitor cells of the such lymphomas 
expressed the EBV latency III program, including EBNA3 expression, as this is the default 
EBV-program after initial B cell infection (1). If EBNA3 expression epigenetically silences 
PRDM1 at this stage as it does in human LCLs (60), this would render the malignant 
progeny independent of EBF1-activation, even after a switch to latency II.  
 
 
Taken together, our findings indicate that shared regulation of PC-differentiation is critical 
for EBF1’s and EBNA3A’s oncogenic activity. Still, the two proteins likely have additional 
non-shared functions during transformation. In the case of EBNA3A one such activity 
might be the observed suppression of Cdkn2a and Bcl2l11. Although knockout of either 
gene was insufficient to promote the expansion of LMP1 B cells, their coregulation might 
still serve this purpose, an issue that remains to be addressed.  
Co-expression of LMP1 and LMP2A, as observed in the EBV growth program, promoted 
B cell expansion and PC-differentiation, but transformation was still restricted to cells that 
did not undergo PC-differentiation. Although EBNA3A suppressed differentiation and 
supported survival of LMP1/2A expressing B cells, it did not promote their transformation, 
but blunted their proliferation through the inhibition of Myc transcription. This is in line with 
reports that EBNA3A overexpression inhibits proliferation of human LCLs by silencing 
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EBNA2-driven MYC-transcription (43), likely through the binding EBNA3A to multiple 
MYC-enhancer sites (66). As one would then predict, overexpression of Myc in 
LMP1_2A/EBNA3A mouse B cells mitigated the repressive effects of EBNA3A and 
allowed their transformation to lymphomas in vivo. This dependence on Myc-activation 
strikingly resembles the dependence of EBV-driven B cell transformation on the MYC-
activator EBNA2 (67). Importantly, transplantation of LMP1, LMP2A, EBNA3A and MYC 
co-expressing B cells caused clonal lymphomagenesis, arguing that transformation of 
such cells still depends on secondary events. Defining such secondary events along the 
lines of the present analysis might shed light on additional functions of other EBV genes 
during the transformation of human B cells. Unexpectedly, EBNA3A did not impact Myc 
transcription in LMP1-only B cells. This might be due to elevated expression of LMP1 
from the R26LMP1 over the R26LMP1t2aLMP2A allele. More likely, and consistent with 
the highly cell type-, signaling- and EBV-dependent selection of Myc-enhancers (68–72), 
integrated LMP1 and LMP2A signaling engages Myc-enhancers distinct from those used 
in LMP1-only B cells and more sensitive to EBNA3A. Such differential use of MYC-
enhancers should be addressed in future studies, albeit in human B cells.  
In summary, our conditional EBV-transgenic mice represent a novel system to study 
interlocking functions of viral oncogenes in B cell lymphomagenesis. The presented data 
reveal a model of EBV-driven B cell lymphomagenesis in which LMPs induce B cell 
proliferation but also promote differentiation to non-transforming PCs. EBNA3A blocks 
PC-differentiation but simultaneously inhibits MYC-driven proliferation. This inhibition 
does not play out in the presence of the EBV MYC-activator EBNA2, allowing B cell 
transformation.  
Methods 
Mouse strains and handling  
Cd19cre (73), Cg1-Cre (74), Rosa26LMP1stopf (21), Rosa26LMP2Astopf (41), 
Rosa26CAS9tg (75), Rag2KO (76), IL2RcgKO (cgKO) (77) and Cd3eKO (78) mouse strains 
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were described before. Unless noted, mice were used between 8 and 30 weeks of age 
and indiscriminately of their sex. Cre- and R26-alleles were always used heterozygous. 
Animals developing pathologies did not succumb to the disease but were sacrificed once 
defined humane termination criteria were reached. Animal procedures were approved by 
the Landesamt für Gesundheit und Soziales Berlin (G0049/15, G0374/13 and G0135/11). 
Data presentation and statistical analysis 
Unless noted otherwise, single dots or indicated n-values represent number of biological 
replicates from independent mice or human donors. Unless noted otherwise, bars 
represent mean ± SD. Two-sided tests for significance were chosen by assumed data 
distribution and variation and are noted in the figure legends. When noted p-values were 
adjusted for multiple testing. 
Data availability  
RNA-sequencing, exome sequencing and array CHG data are available at the GEO 
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Figure legends 
Fig. 1. Ebf1 and Rel are aberrantly activated in LMP1-Lymphoma 
A Experimental overview LMP1-lymphoma (LMP1-L) cohort (B-F) B Survival curve C 
Representative M-FISH of (11;12)-translocations in LMP1-CLs 37 and 43 D 
Translocations in sorted (huCD2+) 2ryLMP1-Ls as determined by exome- and sanger-
sequencing (LMP1-L 31 and 43) or as suggested by CNVs in array-CGH (LMP1-L 37). 
Arrows indicate open reading frame orientation E,F RNA sequencing of sorted splenic B 
cells (CD19+CD38-), tpLMP1 B cells (day 18-20 post transplantation (p.t), huCD2+) and 
2ryLMP1-Ls (huCD2+) E Heatmap showing FPKM-normalized expression F Principle 
component analysis on the 500 most variable genes 
Fig. 2. Ebf1- or Rel-overexpression supports transformation of LMP1 B cells  
A Experimental overview (a-g) B Growth curve of transduced (GFP+) cells C 
Quantification of outgrowing single sorted transduced (GFP+) cells on MEF-feeder. Bars 
represent median outgrowth-frequency. Number of biological replicates showing any 
outgrowth is indicated. Images show representative wells on day 21 post TAT-cre D 
Survival curve of transplanted RAG2KOcgKO mice. E-G Analysis of RAG2KOcgKO mice 
transplanted with 3*105 GFP+ cells. Analysis was performed at symptom onset or 
between day 11 and 22 (control groups). E Representative organ-images day 11 (RV-
GFP/RV-Ebf1) day 21 (RV-LMP1) F FACS-analysis of splenocytes from (E) G Cell count 
of GFP+/huCD2+ cells in indicated organs. n=2 (aCD40/IL-4 treated groups) n=4 (iLMP1 
RV-GFP); n=5 (iLMP1 RV-Ebf1 or iLMP1 RV-Rel) H Human tonsillar GCBs were cultured 
on CD40-L/IL-21 feeder cells and transduced with RVs encoding GFP, LMP1-ires-GFP, 
Ebf1-ires-mCherry or Rel-ires-mCherry. Starting day 5 cells were cultured on feeders 
without CD40-L/IL-21. Fold change of reporter+ cell number on day 12 over day 5 is 
presented (n=15; n=12 (LMP1/RV-Rel and RV-Rel)). All data are presented as mean ± 
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SD. Significance was calculated by Welch’s t-test (G) or one sample t-test (H) 
(*p<0.05;**p<0.005;***p<0.0005) 
Fig. 3. Ebf1 inhibits PC-differentiation of LMP1 B cells  
A-D Further analysis of 2ryLMP1-Ls from Fig. 1 A Heatmap showing FPKM-normalized 
expression of B cell and PC transcription factors (TF) in RNA-sequencing B FACS-
analysis of splenocytes from tpLMP1 mice before lymphomagenesis (day 30 post-
transplant) C FACS-analysis of a representative splenic Ebf1high 2ryLMP1-L D 
Quantification of CD138 expression on huCD2+ cells in (B) and (C). Bars indicate median. 
n=3 (tpLMP1 and Ebf1high LMP1-L), n=9 (Relhigh LMP1-L) E,F RNA-sequencing of iLMP1 
B cells transduced on day 1 with RVs encoding GFP, Ebf1-ires-GFP or Rel-ires-GFP. 
RNA was isolated from FACS-sorted (GFP+/huCD2+) cells on day 6 post TAT-Cre. Naive 
splenic B cells (CD19+/CD38+) from wildtype mice are presented as a control E Heatmap 
showing FPKM-normalized expression F Gene set enrichment analysis of a gene set 
differentially expressed in splenic PCs over GCBs (29) run in the space of genes 
differentially expressed between GFP- and Ebf1-transduced iLMP1 B cells on day 6.  
Fig. 4. EBNA3A inhibits PC-differentiation  
A iLMP1 B cells were transduced with RVs encoding mCherry or indicated EBNAs 
(reported by ires-mCherry). FACS-based quantification of mCherry+ cells day 7 over day 
4 is presented (n=5) B-F Analysis of Cd19-cre;R26EBNA3Astopf and Cd19-
cre;R26BFPstopf mice B Representative FACS-analysis of spleens C Survival curve D 
Quantification of BFP expression in bone marrow pro- (CD93+B220+IgM-IgD-CD19+c-
kit+/low), pre- (CD93+B220+IgM-IgD-CD19+c-kit-), immature- (CD93+B220+IgM+IgD-) and 
splenic mature- (CD93-B220+CD19+IgM+IgD+) B cells. n=9 (Cd19-Cre;BFPstopf) n=10 
(Cd19-Cre;EBNA3Astopf) E Representative FACS-analysis and quantification of BFP 
expression in bone marrow (CD138+CD267+) PCs; n=12 (Cd19-Cre;BFPstopf) n=14 
(Cd19-Cre;EBNA3Astopf) F Elispot for total ASCs in sorted BFP+ bone marrow cells; n=6. 
Images show representative wells with 4*104 cells. All data are presented as mean ± SD. 
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Significance was calculated using a one-way Anova with P-value adjusted via Dunnett 
(A), two-way Anova with Sidak’s multiple comparisons test (D), Mann-Whitney U test (E), 
Welch’s t-test (F) (*p<0.05;**p<0.005;***p<0.0005;n.s. non-significant) 
 
Fig. 5. EBNA3A inhibits PC-differentiation and supports expansion of LMP1 
B cells 
A-D iBFP, iEBNA3A, iLMP1 and iLMP1/EBNA3A B cells A Growth curve of bulk cultured 
cells. n=4, n=5 (iLMP1) B FACS-based quantification of BrdU-uptake on day 6 post TAT-
Cre. n=6 C FACS-based quantification of active-caspase 3 on day 6 post TAT-Cre. n=10 
D Heatmap showing FPKM-normalized gene expression in RNA-sequencing performed 
on sorted hucd2+ (iLMP1) or huCD2+BFP+ (iLMP1/EBNA3A) cells day 6 post TAT-Cre. 
Splenic naïve (CD19+CD38-) B cells (from Fig. 3E) serve as a control E-H RAG2KOcgKO 
mice were reconstituted with fHSPCs from Cd3eKO;Cd19-Cre;R26LMP1stopf (tpLMP1) or 
Cd3eKO;Cd19-Cre;R26LMP1stopf/EBNA3Astopf (tpLMP1/EBNA3A) mice. E Survival curve F 
Representative image of spleens and quantification of splenic weight at symptom onset 
(tpLMP1/EBNA3A) or day 32-41 p.t. (tpLMP1); n=3 (RAG2KOcgKO), n=6 (tpLMP1), n=10 
(tpLMP1/EBNA3A) G Immuno-histology on splenic sections day 36 p.t. (representative 
for 3 independent mice per group). Splenic section of a RAG2KOcgKO mouse is presented 
as negative control H Elispot for total ASCs in sorted reporter+ splenic cells at symptom 
onset or day 32-41 p.t. (tpLMP1). Quantification was normalized to mean ASC-frequency 
in tpLMP1 conditions. Images show representative wells with 1.5*105 cells. n=6 (tpLMP1), 
n=4 (tpLMP1/EBNA3A). All data are presented as mean ± SD. Significance was 
calculated using a student’s t-test (A,B,C,F) or Welch’s t-test (H) (*p<0.05; **p<0.005; 
***p< 0.0005)  
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Fig. 6. EBNA3A blocks PC-differentiation of LMP1 and LMP2A B cells.  
A Experimental overview (B-D) B Representative FACS-analysis of spleens from donor 
animals and recipient animals at 7-28 days p.t (quantification in Fig. S6A). C Survival 
curve D Representative images of LMP1/2A+ lymphomas arising in (C) E Representative 
FACS-analysis and quantification of CD19/CD138 expression on huCD2+GFP+ cells in 
lymphomas arising in (C); n=3 F,G iLMP1, iLMP1_2A and iLMP1_2A/EBNA3A B cells 
analyzed day 9 post TAT-Cre F FACS-based quantification of CD138+/B220low PCs ; n=3 
(iLMP1), n=11 (iLMP1_2A), n=9 (iLMP1_2A/EBNA3A) G Elispot for total ASCs among 
sorted reporter+ cells. Images show representative wells with 120 cells; n=9 H,I 
RAG2KOcgKO mice were reconstituted with fHSPCs from Cd3eKO;Cd19-Cre 
R26LMP1_LMP2Astopf (tpLMP1_2A) or Cd3eKO;Cd19-Cre 
R26LMP1_LMP2Astopf;EBNA3Astopf (tpLMP1_2A/EBNA3A) mice. H Survival curve I 
Representative FACS-analysis of splenocytes from tpLMP1_2A/EBNA3A mice at 
symptom onset. Quantifications shows expression of LMP1_2A (huCD2+) and EBNA3A 
(BFP+) in whole splenocytes or CD19/CD138 expression on indicated populations. n=7. 
All data are presented as mean ± SD. Significance was calculated using a Mann-Whitney 
U test (G,I), or one-way Anova with p-value adjusted via Dunnett (F) 
(*p<0.05;**p<0.005;***p< 0.0005) 
 
Fig. 7. Transformation of LMP1_2A B cells requires overexpression of 
EBNA3A and Myc 
A-H Analysis of iEBNA3A, iLMP1, iLMP1_2A and iLMP1_2A/EBNA3A B cells A 
Representative FACS-analysis and quantification of BrdU-incorporation day 6 post TAT-
Cre; n=7 (iLMP1_2A), n=6 (iLMP1_2A/EBNA3A) B RT-qPCR-based quantification of 
Myc-expression day 6 post TAT-Cre; n=17 (iLMP1), n=14 (iLMP1/EBNA3A), n=11 
(iLMP1_2A and iLMP1_2A/EBNA3A) C Western blot of total cell lysates day 6 post TAT-
Cre. Mychigh LMP1- LMP2A- mouse cell line 19pp serves as expression-control D 
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Experimental overview (E-H). iEBNA3A cells were stimulated with αCD40 (2µg/ml) and 
IL-4 (20ng/ml) to allow transduction. E Growth curve of transduced (GFP+ or mCherry+) 
cells in bulk F Representative FACS-analysis and quantification of BrdU-uptake on day 6 
post TAT-Cre; n=6 G-H Analysis of RAG2KOcgKO mice transplanted with transduced cells 
of 3 independent donors per group G Survival curve H Representative organ images and 
FACS-analysis of mice transplanted with RV-Myc transduced iLMP1_2A/EBNA3A B cells 
at disease onset. Quantifications show BFP/mCherry-expression in huCD2+ cells and 
CD19/CD138-expression on huCD2+/BFP+/mCherry+ cells. n=3. All data are presented 
as mean ± SD. Significance was calculated using a student’s t-test (A), Man-Whitney U 
test (B), or paired student’s t test (E,F) (*p<0.05;**p<0.005;***p<0.0005;n.s. non-
significant) 
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Supplemental Material and Methods 
 
Mouse strains and handling  
Rag2KOcgKO mice used as recipients the initial LMP1-lymphoma cohort (Fig. 1A) had a 
C57BL/6J x C57BL/10SgSnAi genetic background (Taconic). All other mice were generated 
on or backcrossed for more than 10 generations to C57BL/6. Up to 6 mice per cage were 
housed under specific pathogen–free conditions (FELASA) in individually ventilated cages 
in a room illuminated in a 12h light-dark cycle, with access to water and autoclaved standard 
pellet chow ad libitum. All cages contained 5mm of aspen chip and tissue wiles for bedding 
and a mouse house. Experimental mice were fed with acidified water pH [2.5-3]. 
Cell culture 
Cells were cultured at 37°C and 5% CO2 in a humidified incubator. Unless noted otherwise, 
cell culture media and supplements were purchased from Thermo Fisher. PLAT-E (cell 
biolabs) and CD40-L/BAFF feeder cells (40LB) (1) were grown in standard culture medium 
(SCM - glutamine, pyruvate and glucose containing (full) DMEM supplemented with 10% 
FCS. Mouse embryonic fibroblasts (MEF) were grown in MEF-Medium (MEFM - full DMEM 
supplemented with 10% FCS, 1x non-essential amino acids (NEAA), 1x 
Penicillin/Streptomycin (Pen/Strep) and 1x GlutaMAX). LMP1-lymphoma cell lines were 
cultured in 15% B cell medium (BCM15 - full DMEM with 15% FCS, 1x GlutaMAX, 100mM 
HEPES , 1x NEAA, 1x Pen/Strep and 52µM β-mercaptoethanol (β-Me)). Primary mouse B 
cells and 19pp mouse Burkitt lymphoma cell line (2) were cultured in 10% B cell medium 
(BCM10 - full DMEM with 10% FCS, 100mM HEPES, 1x NEAA, 1x Pen/Strep and 52 µM β-
Me). Mouse embryonic stem cells (ES-cells) were cultured in ES-cell medium (ESM - 
KnockOut™ DMEM - supplemented with 15% FCS, 1x NEAA, 2mM L-glutamine, 300U/mL 
ESGRO/LIF (Merck) and 100µM β-Me).  
MEF isolation 
 MEFs were isolated according to standard procedures (3). MEFs in passage 3 were treated 
with 10µg/ml mitomycin (Sigma) for 2h at 37°C and subsequently washed 2x with PBS. In 
the manuscript MMC-treated passage 3 MEFs are referred to as MEFs. 
Embryonic stem cell culture and targeting 
R26-targeting vectors were digested with AsiSI (NEB) at 37°C overnight. Linearized-DNA 
was purified by 2x Phenol:Chlorophorm:Isoamylalcohol (25:24:1) and 1x Chloroform 
extraction. DNA was precipitated with 0.1vol 3M NaOAc and 2vol of Ethanol at -20°C over 
night. DNA was washed with 70% Ethanol and dissolved in H2O to a concentration of 
0.5µg/µl. ES-cells were cultured on MEFs in ESM on gelatin-coated tissue culture plates to 
maximum sub-confluency and medium was changed daily. For electroporation, ES-cells 
were washed 1x with PBS [pH 7.4] and trypsinized. Trypsinized cells were washed 1x with 
PBS [pH 7.4] and resuspended in RPMI 1640 without phenol red (Thermo Fisher) to a 
density of 1.25 x 107 cells/ml. 1x107 cells were then electroporated with 25μg linearized 
targeting vector using a GenePulser (Biorad - 0.4cm cuvettes, 230V and 500μF). 
Electroporated cells were cultured on 2-3 MEF-coated 10cm-dishes. 24h post 
electroporation ESM was supplemented with 200μg/mL G418. After 7 days G418 (Sigma) 
resistant colonies were picked, dissociated with 1x Trypsin supplemented with 1% chicken 
serum and expanded on MEF-coated plates in G418-ES-medium. Expanded ES-cell clones 
were analyzed for correct integration by southern blot.  
Blastocyst injection 
On the day of blastocyst injection sub-confluent ES-cells were detached using ESGRO 
accutase (Merck) for 5min at 37°C. Detached cells from one 10cm dish were transferred in 
5ml G418-free ESM to gelatin-coated 6cm-dish for 15min at 37°C to allow attachment of 
MEFs. ES-cells in the supernatant were collected, pelleted and resuspended in 1ml injection 
buffer (full DMEM with 10% FCS, 100mM HEPES, 1x Pen/Strep and 300U/ml DNAse 
(Sigma)). Blastocyst injection of ES-cells was performed in the transgenic core facility of the 
MDC according to standard protocol. 
 
Cell preparation from mouse organs 
Cells from spleen, liver and tumors were prepared by grinding the organ/tumor between two 
frosted object slides in B cell prep medium (BPM - full DMEM supplemented with 1% FCS 
and 1mM EDTA). Bone marrow was prepared by flushing femur and tibia with BPM using a 
syringe. Single cell suspensions were depleted for red blood cells by resuspending cells 
500µl BPM and mixing them with 5ml Gey solution [3.5mL H2O, 1mL Gey A (35g/L NH4Cl, 
1.85 g/L KCl, 1.5g/L Na2HPO4 x 12 H2O, 0.12g/L KH2PO4, 5g/L glucose, 50 mg/L phenol 
red), 0.25mL Gey B (4.2g/L MgCl2 x 6 H2O, 1.4g/L MgSO4 x 7 H2O, 3.4g/L CaCl2), 0.25mL 
Gey C (22.5g/L NaHCO3)]. After 3min lysis was stopped with 5ml BPM. Cells passed 
through a 70µm filter, pelleted (8min; 1200rpm), resuspended in BPM and counted with a 
casy-cell counter (OLS). To deplete non-B cells, splenic cells were incubated with anti-CD43 
MACS-beads (Miltenyi- 40µl beads in 600µl BPM) for 25min on ice. Labeled cells were 
washed with 10ml BPM and pelleted. Cells were resuspended in BPM and passed through 
magnetic LR-columns (Miltenyi). CD43- B cells in the flow through were pelleted and 
resuspended in BCM10.  
 
HSPC transplant  
Rag2KOcgKO mice were xray-irradiated (3gy) using a RS-2000 (Radsource). 3 days before 
up until 14 days post irradiation, mice were fed 0.2% Neomycin-sulfat (bela-pharm) in the 
drinking water. 24h post irradiation mice were iv-injected with 1000 FACS-sorted fetal liver 
(E16.5) Lineage-Sca+c-Kit+ LSK cells (referred to as HSPCs) and 1*106 Rag2KOcγKO bone 
marrow carrier cells in PBS supplemented with 2% FCS (lineage markers: B220, CD19, 
Ter119, CD11b, CD11c, Gr1.1. and CD3ε). HSPCs for reconstitution were derived from at 
least 2 independent fetal donors. 
Cell and tumor transfer 
Single cell suspensions in 2% FCS (Thermo Fisher) in PBS were injected into the tail vein 
of recipient mice. Cγ1-Cre;LMP1/2A B cells were FACS-sorted (CD19+) before transfer. RV-
transduced B cells were transplanted as bulk (i.e. mix of transduced and non-transduced 
cells). Indicated numbers of transplanted cells in the figures represent total transduced 
reporter+ cells that were transferred. Cells from at least 2 independent donors were used.  
TAT-Cre treatment  
B cells were washed 3x with PBS at 4°C and incubated with 60µg TAT-Cre (4) in Hyclone 
media (Thermo Fisher) at 37°C for 40min. When indicated, cells were retrovirally transduced 
24h after TAT-Cre treatment. B cells expressing TAT-Cre induced transgenes are referred 
to as i(“transgene”) B cells. 
 
B cell stimulation and plasma blast-differentiation in vitro 
B cells were stimulated with 2µg/ml LEAF-purified αCD40-antibody (Biolegend) and 20ng/ml 
IL-4 (R&D systems). To differentiate B cells in plasma blasts, αCD40/IL-4 stimulated cells 
were washed on day 2 with PBS and cultured on irradiated (12 gray) 40LB feeder cells in 
the presence of 20ng/ml IL-21 (R&D systems). When indicated, cells were retrovirally 
transduced 24h after stimulation. 
 
Retroviral transduction 
PLAT-E MSCV-packaging cells were transfected with MSCV-vectors using Fugene 
(Promega) according to the manufacturer’s instructions. 24h post transfection medium was 
exchanged. 48h post transfection virus containing PLAT-E supernatant was collected and 
sterile filtered (0.45µm). For viral transduction, tissue culture dishes were coated with 50 
µg/ml retronectin (Takara) at 4°C over-night. Coated dishes were washed with PBS and 
blocked with 2% BSA in PBS for 30min at RT. Blocked plates were incubated with PLAT-E-
supernatant at RT for 30min. Cells were mixed 1:1 with PLAT-E-supernatant, transferred to 
virus-coated plates and spin-transduced at 2000 rpm/27°C for 90min in the presence of 
4µg/ml polybrene (Sigma). 24h post transduction the medium was exchanged.  
 
Single cell transformation 
iLMP1 B cells or αCD40/IL-4-stimulated CD43- B cells from R26LMP1stopf mice were 
transduced with empty MSCV-ires-GFP or MSCV-ires-GFP encoding Ebf1-ires-GFP or Rel-
ires-GFP 24h post TAT-Cre or stimulation. On day 3 single GFP+ cells were FACS-sorted 
into MEF-coated 96-wells containing 100µl BCM15. After 2 weeks wells with outgrowing 
GFP+ colonies were counted using a BZ 9000 fluorescence microscope (Keyence). 
 
BrdU incorporation  
In vitro cultured cells were incubated with 10µM BrdU (BD). After 16h life cells were labeled 
for 15min at RT by zombie aqua exclusion (Biolegend). Cells were fixed and BrdU was 
detected with a APC-BrdU FACS-labeling kit (BD) according to the manufacturer’s 
instructions. BFP was detected by simultaneous staining with an Alexa 488-conjugated 
αGFP antibody (Thermo fisher). In experiments including BFP+/GFP+ double positive cells, 
all cells were FACS-sorted for reporter expression prior to the staining. Reporter staining 
was then excluded from the final analysis.  
Active Caspase 3 staining  
FACS-sorted reporter+ cells were fixed and stained for active caspase 3 using a PE-Active 
caspase-3 apoptosis kit (BD) according to manufacturer’s instructions. 
Cell cycle analysis 
FACS-sorted reporter+ cells were washed with cold PBS and fixed with ice cold methanol 
(66% in PBS) for 2h. Fixed cells were pelleted and rehydrated with PBS for 15min. 
Rehydrated cells stained with 30µg/ml PI and 100µg/ml RNAse for 30min in PBS.  
FACS staining, analysis and sorting 
Cells were incubated with 10µg/ml TruStain fc-block (Biolegend) in FACS-buffer (PBS 
supplemented with 1% FCS, 1mM EDTA and 0.05% Sodium Azide) for 20min. Fc-blocked 
cells were stained with fluorophore- and/or biotin-labelled antibodies (1:200) in FACS-buffer 
for 30 min. Antibodies are listed in SI-Appendix Table A. Samples with biotin-labeled 
antibodies were washed 2x in FACS-buffer and stained with Streptavidin-conjugated 
fluorophores in FACS-buffer for 30 min. Stained cells were washed 1x with FACS-buffer and 
acquired with a FACS-Fortessa (BD). Human GCB cells were acquired on an LSRII (BD). 
Cell sorting was performed on an FACSAria (BD). FACS-files were analyzed using the 
FlowJo software (flow-jo). In all analysis dead cells were excluded by FSC/SSC (in vitro) or 
FSC/SSC and zombie aqua or PI exclusion (ex vivo). Cells analyzed were pre-gated for 
every indicated transgene. In iLMP1, iLMP1_2A, iLMP1/EBN3A and iLMP1_2A/EBNA3A 
cultures all blasting cells are huCD2+, we therefore used, unless noted otherwise, blasting 
as a surrogate reporter for LMP1 or LMP1_2A expression. Cell counting of in vitro cultured 
cells was performed in FACS-analysis using counting beads.  
Elispot 
Multiscreen protein binding plates (Merck) were activated with 35% ethanol in PBS, washed 
with PBS and incubated with anti λ- and κ-light chain antibodies 1:1000 in PBS for 16h at 
4°C. Plates were blocked with BCM10 for 30min at 37°C. Reporter+ FACS-sorted cells were 
seeded on coated plates in BCM10 and incubated for 16h. Plates were washed 6x with 
PBS/0.1% Tween and incubated with biotin coupled anti λ- and anti κ-light chain antibodies 
in 1:500 PBS/0.1% Tween for 2h at 37°C. Plates were washed with deionized water and 
incubated with 1:3000 streptavidin-AP in PBS at RT of 30min. Plates were washed with 
deionized water and stained with BCIP/NBT color development substrate (Promega). Plates 
were imaged using immune-spot-imager (CTL) and large spots were counted by immune-
spot-imager software (CTL). When freeze/thawed cells were used, the frequency of antibody 
secreting cells (ASC) was presented as relative frequency over control cells. Elispot-
antibodies can be found in SI-Appendix table A. 
Western blot 
Cell were lysed in RIPA buffer (20mM Tris-HCl [pH 7.5] ,150mM NaCl, 1mM EDTA, 1% NP-
40, 0.1% SDS, 0.1% sodium Deoxycholate) supplemented with 1x c0mplete protease 
inhibitors (Sigma) for 20 min on ice. Nuclei were pelleted. Lysate was heated in 1x SDS-
sample buffer for 3min at 96°C (6 x SDS-sample buffer; 250mM TRIS [pH 6.8], 38% glycerol, 
10% SDS, 5% b-Me, 0.01% bromphenol blue). Proteins were separated by SDS-gel-
electrophoresis and transferred to PVDF membranes. Membranes were blocked with 5% 
skim milk power in 1xTBST (50mM Tris [pH 7.6]; 150mM NaCl; 0.05% Tween 20). Primary 
antibodies were incubated 1:1000 in 1xTBST. Filtered supernatant from LMP1-antibody 
secreting hybridoma (S12) was incubated as is. Membranes were washed 5x with TBST 
and incubated with HRP-coupled secondary antibodies were at 1:10000 in 1x TBST. 
Membranes were imaged using ECL-solution (VWR) and a fusion SL–imager (Vilber). 
Images were trimmed and level corrected (without gamma correction) by Photoshop 
(Adobe). Antibodies are listed in SI-Appendix Table A. 
HA-Co-immunoprecipitation 
10*106 stimulated B cells were washed 2x with cold PBS and lysed in 500µl IP lysis buffer 
(0.5% Tween20, 25mM Tris [pH 8.0], 200mM NaCl, 2mM EDTA, 5mM NaF, 1mM sodium 
orthovanadate, 2mM Sodium Pyrophosphate, 1x c0mplete protease inhibitor) for 25min on 
ice. Nuclei were pelleted and supernatant was incubated with 10µl of Sepharose-A 
Dynabeads (Thermo Fisher) coupled to 5µl of anti-HA antibody (cell signaling) for 4h rotating 
at 4°C. Beads were washed 3x with IP lysis buffer at 4°C. Washed beads were boiled in 
SDS-sample buffer at 96°C for 5min.  
Isolation of genomic DNA 
gDNA was extracted using the DNeasy blood and tissue-kit (Quiagen) or Nucleo-spin tissue 
kit (Machery Nagel) according to the manufacturer’s instructions.  
PCR and Agarose gel extraction 
PCR was performed on 100ng DNA using Herkulase (Agilent) or KOD-Polymerase (Merck) 
(for VDJ-PCR) and a according to the manufacturer’s instructions. PCR fragments were 
isolated from agarose gels using a PCR-cleanup gel-extraction kit (Machery-Nagel). Primers 
are listed in SI-Appendix Table B. 
CAS9 knockout efficiency estimation with the Inference of CRISPR Edits (ICE) tool 
Sanger-sequencing files of PCR products spanning the sgRNA targeting-site in targeted and 
non-targeted controls were compared by Synthego-ICE-software to estimate KO-efficiency 
(https://ice.synthego.com) (5). 
Southern blot 
5µg of gDNA was fully digested with EcoRI, or PacI (both Promega) and separated by 
electrophoresis on a ethidium bromide containing 0.7% agarose gel in 1x TAE buffer (0.04M 
Tris, 0.02M acetic acid, 1mM EDTA). The DNA-gel was 2x washed in deionized water and 
incubated for 2x 15min in 0.125M HCl. Next, gel was washed 2x in deionized water and 
incubated in transfer buffer (1.5M NaCl /0.5M NaOH) for 2x 15min. DNA was transferred 
over night at RT with transfer buffer by southern blotting to a pre-activated (5min H2O, 15min 
transfer buffer) Hybond-XL nylon-membrane (Amersham). After transfer, the membrane 
was neutralized for 10min in neutralization buffer (0.5M Tris [ pH7.2], 1M NaCl). Membrane 
was dried, crosslinked to DNA with a UV-Crosslinker (Stratalinker) and incubated in 
Express-HYB (Takara) at 65°C for 30min. Radioactive probes were generated using 32P-
CTP and the Ladderman labelling kit (Takara) according to the manufacturer’s instructions. 
Labeled probes were purified using ProbeQuant™ G-50 Micro Columns (GE) and denatured 
at 96°C for 5min followed by 5 min on ice. The membrane was incubated with the probe in 
ExpressHYB at 65°C for 18-24h. The excess probe and unspecific labelling was removed 
by washing the membranes 3 times with SSC buffers for 30 min at 65°C. 1st wash 2 x SSC 
(0.3M NaCl, 0.03M sodium citrate/0.1% SDS). 2nd wash 1 x SSC/0.1% SDS. 3rd wash 0.5 x 
SSC/0.1% SDS, respectively. Finally, the membrane was enclosed in a plastic foil and 
exposed to a CL-Xposure film (Thermo Fisher) at -80°C. 
 














































Sample gDNA was derived from 2ryLMP1 lymphomas FACS-sorted for huCD2 expression. 
Tail-DNA was derived from flHSPC-donor fetuses. Array CGH was performed and analyzed 
as described before (6). In brief 250ng of genomic DNA of tumor and tail-DNA of donor 
animal were labelled with Cy3-dCTP and Cy5-dCTP, respectively using the Cytag kit (Enzo). 
The labelled nucleotides were purified using Microcon xym-30 columns (Merck) prior 
hybridization onto mouse 8 x 60k array CGH arrays (Agilent) with the design ID 82410 
followed by washing and scanning according to the manufacturer’s protocol.  
Library preparation for exome sequencing 
Exome-libraries of gDNA were created with the SureSelect (XT) Mouse All Exon Kit, 
according to the manufacturer’s instructions and sequenced on an Illumina NextSeq 500. 
SNP calling from exome sequencing 
Paired-end reads were mapped to the mm10 reference genome (ftp-
mouse.sanger.ac.uk/ref/GRCm38_68.fa) using bwa-mem(7). In BAM files PCR duplicates 
were marked, read groups were added, and reads were realigned locally around indels. 
After local re-alignments, pair mate information was fixed and read scores calibrated using 
Picard tools version 1.141 (Broad Institute). Reads from different lanes were merged to a 
single BAM file per sample, and PCR duplicates were removed again. Mutations were called 
using MuTect version 1.1.7 (8) by comparing tumor samples to tail-samples of the fHSC-
donor fetus. Most deleterious mutation effects were predicted using the Ensembl Variant 
Effect Predictor (VEP) (9). Variants with an allele frequency above 0.35 were considered as 
clonal.  
Translocation mapping from exome sequencing 
Genomic fusions were identified in exome sequencing reads using FACTERA version 1.4.4 
(10), using the mm10 reference genome from Sanger and the following parameters: 
 
Minimum breakpoint-spanning reads for each fusion (r): 5 
Minimum discordant reads for each candidate fusion (m): 2 
Maximum breakpoints to examine for each read pair (x): 5 
Minimum reads with same breakpoint required (s):   1 
Minimum fraction of read bases for fusion template alignment (f):   0.9 
Minimum % similarity for read to match fusion template (S):  0.95 
K-mer size for fragment comparison (k): 12 
Minimum size of soft-clipped read region (c):  16 
Number of bases flanking breakpoint for fusion template (b): 500 
Number of threads for blastn search (p):   4 
Number of bases flanking breakpoint to provide in output (a):  50 
 
The results were filtered for translocations with one end within chr12: 113,153,879 - 
116,047,724 (Igh-locus) or chr6: 67,491,855 - 70,765,720 (Igk-locus) or chr16: 18,970,309- 
19,284,104 (Igl-locus). 
RNA-extraction 
RNA was isolated by RNeasy kit (Quiagen) including a DNAse digestion step according to 
the manufacturer’s instruction. 
RT-qPCR 
RNA was transcribed into cDNA by superscript III (Thermo Fisher) using random hexamer 
primers according to the manufacturer’s instructions. 5-8ng of cDNA of FACS-sorted cells 
was amplified using a Power-SYBR-Green RT-PCR-kit (Thermo Fisher) and a STEP-ONE-
PLUS RT-qPCR-cycler (Applied Biosystems). Analysis was done by ΔΔCT-method, using 
HPRT as a housekeeping control gene. Every data point represents the mean of 2-3 
technical replicates in one biological replicate. Primers are listed in SI-Appendix Table B. 
Library preparation for RNA-sequencing 
For RNA-sequencing of tumor samples, RNA was isolated from FACS-sorted (huCD2+) non-
transformed tpLMP1 B cells (day 18-20 post transplantation), FACS-sorted (huCD2+) 
2ryLMP1 lymphomas, or FACS-sorted (CD19+/CD38+/FAS-) naïve splenic B cells from 
C57BL/6. RNAseq libraries were prepared with the TruSeq Stranded mRNA kit (Illumina), 
and 50bp single end sequencing was performed on a HiSeq™ 2000 Sequencing System 
(Illumina). For RNA-sequencing of in vitro cultured cells, RNA was isolated from FACS-
sorted (reporter+) B cells at day 6 post tat-cre, or FACS-sorted (CD19+/CD38+) naïve splenic 
B cells from C57BL/6 mice. RNAseq libraries were prepared using the NEBNext® Ultra™ II 
Directional RNA Library Prep Kit for Illumina (NEB) and was sequenced in a 2x76 cycle run 
on a HiSeq 4000 (Illumina). 
RNA-sequencing analysis 
Reads were mapped and gene expression quantified using PiGX (11), an integrated pipeline 
for read trimming, mapping, quality control, and gene expression quantification. Reads 
counts assigned to genes were transformed using a variance stabilizing transform (VST) 
(12) with the DESeq2 R package (version 1.22.2) (13) using R version 3.5.1. The gene 
expression matrix was filtered to only include genes with at least one read in one of the 
samples. Principal component analysis was performed using the 500 genes with the highest 
variance (in VST). Xist and immunoglobulin heavy and light chain genes were excluded from 
the principal component analysis to avoid biasing the results by gender or Ig-usage.  
Gene set enrichment analysis 
Gene expression data for mouse splenic plasma cells (SplPC) and germinal center B cells 
(GCBC) from Shi et al. (14) were downloaded from the gene expression omnibus 
(GSE60927). Differential expression analysis was run using DESeq2, contrasting SplPC 
with GCBC. SplPC-induced genes were identified as genes with log2 fold change above 2, 
and SplPC-repressed genes (GCBC-specific genes) were identified as genes with log2 fold 
change below 0.5.  Immunoglobulins variable genes and Xist were excluded. DESeq2 was 
also done contrasting Ebf1- and GFP-expressing iLMP1 B cells on day 6 post TAT-Cre. 
Genes with an adjusted P value below 0.005 were kept. Selected genes were then ordered 
by their log2 fold change to generate the ranked gene list for GSEA. Immunoglobulin 
variable genes and Xist were excluded. 
 
The ranked gene lists and induced/repressed gene sets were then input to the GSEApy 
package (version 0.9.13,https://github.com/zqfang/GSEApy) and analyzed using the 
GSEAPreranked module. 
Analysis of NF-kB target genes  
LMP1/NF-kB targets-genes previously defined by Cahir-McFarland et al (15) were used to 
cluster samples using VST counts (DESeq2), using euclidean distances and average 
linkage. Z scores were computed by subtracting from each sample the population mean and 
dividing by the gene’s standard deviation. 
Cloning of MSCV-expression vectors 
pMIGR1 (MSCV-ires-GFP) (16) and pMIB (MSCV-ires-BFP) were a kind gift from Martin 
Janz (Charite Berlin). MSCV-ires-mCherry was derived from MSCV-ires-GFP by substituting 
the eGFP-ORF (NcoI/SalI-fragment) with mCherry-ORF. MSCV destination vectors were 
created by inserting a gateway destination cassette into the XhoI-site upstream of the ires. 
ORFs of EBV/B95-8 EBNA1, EBNA-LP, EBNA3A, 3B and 3C were a kind gift of Elliott Kieff 
and Benjamin Gewurz an Bo Zhao (Harvard Medical School, Boston). EBV/B95-8 EBNA2 
ORF was a kind gift of Wolfgang Hammerschmidt (Helmholtz Zentrum, München). Mouse 
Myc-, Rel- and Ebf1-ORFs were cloned from splenic cDNA from C57BL/6 mice. A HA-tag 
(TAC CCA TAC GAT GTT CCA GAT TAC GCT) was inserted via PCR with overhanging 
primers 5’ of the EBNA1-, EBNA2-, EBNA3A-, 3B- and 3C-ORFs and 3’ of the EBNALP-
ORF. PCR-amplicons of all ORFs were cloned into pENTR entry vectors by pENTR/D-
TOPO cloning kit (Thermo Fisher) and shuttled into MSCV destination vectors by LR-
recombination with Gateway LR Clonase II (Thermo Fisher). Guide RNAs were expressed 
from MSCV-pU6-(BbsI)-CcdB-(BbsI)-Pgk-Puro-T2A-BFP (MSCV-sg-BFP) (17) and MSCV-
pU6- (BbsI)-CcdB-(BbsI)-Pgk-Puro-T2A-mCherry (MSCV-sg-mCherry). MSCV-sg-mCherry 
was derived from MSCV-sg-BFP by substituting the BFP-ORF with an mCherry-ORF. 
sgRNAs were designed by CrispRGold (17) and inserted into the BbsI-site of MSCV-vectors. 
sgRNA sequences are indicated in supplemental information appendix table S2. 
Cloning of Rosa26 targeting vectors 
EBV/B95-8 ORFs of LMP1 and LMP2A were derived from gDNA of R26LMP1stopf and 
R26LMP2Astopf transgenic mice (18). The LMP1t2aLMP2A ORF was created by overlap-
extension PCR, inserting a sequence encoding t2a self-cleavage peptide 
(gagggcagaggaagtctgctaacatgcggtgacgtcgaggagaatcctggacct) between LMP1 and LMP2A 
ORFs. The STOP codon of LMP1 was eliminated in the 2A-construct. The LMP1t2aLMP2A-
ORF was inserted into a pENTR vector by pENTR/D-TOPO cloning kit (Thermo Fisher). 
pR26-huCD2-Dest was created by inserting a gateway destination cassette into the PacI-
site of pR26-huCD2 (2). Targeting vectors pR26-LMP1t2ALMP2A-ires-huCD2stopf and 
pR26CAG-EBNA3A-HA-ires-BFPstopf were created using LR Clonase II (Thermo Fisher) to 
shuttle ORFs from pENTR-LMP1t2aLMP2A and pENTR-EBNA3AHA into pR26-huCD2-
Dest and pR26-CAG/BFP-Dest (19), respectively. To generate pR26-BFP-ires-huCD2stopf, 
the ORF of eBFP2 was cloned into the AscI-site of pR26-huCD2. The eBFP2 template was 
derived from MSCV-ires-BFP. 
Histology 
Histology staining was performed and graded by the pathology core facility of the 
Universitätsklinikum Heidelberg. Organs were fixed with formalin (Sigma) for at least 48h. 
After fixation, representative specimens of spleen, liver and lung were routinely dehydrated, 
embedded in paraffin, and cut into 4-mm-thick sections. Sections were stained with an 
Autostainer (Dako) using standard conditions. In brief, sections were deparaffinated by 
sequential incubation in Xylol (2x10min), 100% Ethanol (2x5min), 96% Ethanol (2x5min), 
70% Ethanol (2x5min) and then transferred to H20. Sections were boiled in a pressure 
cooker in pH 6-Buffer (Dako) for 10min. After sections were chilled for 30min in in pH 6-
Buffer. Sections were than boiled for 10min in in pH 9-buffer (Dako) at normal pressure and 
subsequently chilled for 30min. Sections were stained with primary antibodies BCL6 
(ProteinTech Europe), IRF4/Mum1 (ProteinTech Europe) and CD10 (St. John’s Laboratory) 
diluted in antibody diluent (Dako) for 30min. Sections were washed with TBS/Tween and 
incubated with secondary antibody (1:200 in antibody diluent) for 20min. Sections were 
washed with TBS/Tween and stained with “REAL Detection System” (DAKO) according to 
the manufacturer’s instructions. For counterstain sections were incubated with 5min 
Hämalaun nach Mayer, followed by 5 min of H2O. samples were than mounted in Auatex 
(Merck) and imaged with a NanoZoomer whole slide imager (Hamamatsu). Used antibodies 
are listed in SI-Appendix Table A. 
Immunofluorescence and immunohistology  
Cryostat-sections of OCT (Tissue-Tek) embedded organs were fixed with 100% acetone for 
20min at RT. Sections stained for c-Rel were fixed 2h in 4% Paraformaldehyde in PBS, 
washed with PBS and fixed again with 100% Acetone for 20 min. Cultured cells were settled 
in PBS on Poly-D-lysine coated object slides and fixed with ice-cold methanol/acetone (1:1 
vol/vol) for 2min. Fixed sections or cells were rehydrated in PBS for 15min and blocked with 
2% BSA in PBS for 30min. Sections for c-Rel detection were blocked and permeabilized for 
2h with 1% Triton-X100 in 3% BSA/PBS. Primary antibodies were incubated in PBS 0.2% 
BSA for 16h at 4°C. Sections were washed with PBS and incubated with secondary or 
fluorophore conjugated antibodies in PBS 0.2% BSA for 2-16h at RT. Slides were washed 
and incubated with 1µg/ml DAPI in PBS. Stained sections were mounted with Flouromount 
(Sigma) and imaged with a BZ-9000 microscope (Keyence). Images were trimmed and level 
corrected (no gamma correction) by Photoshop (Adobe). Images shown in the same panel 
were identically acquired and processed. Used antibodies are listed in SI-Appendix table A. 
Multiplex-FISH (M-FISH) 
To create metaphase spreads LMP1-lymphoma cell lines were cultured in 135ng/ml 
colcemid (Thermo Fisher) for 4h at 37C°. Cells were resuspended in 200µl PBS. 10ml 
hypertonic buffer (37.5mM KCl, 0.5% Sodium Citrate w/v, 37°C) was slowly added to cell 
suspension and incubated for 20min at 37°C. Cells were pelleted at 400g and resuspended 
in 200µl residual supernatant. Cells were fixed with cold methanol/glacial acetic acid (3:1 
vol/vol) 4C°. Cells were pelleted at 400g at 4°C and resuspended in 200µl residual 
supernatant. Fixation step was repeated 3 times. Fixed cells were dropped on glass slides 
to create Metaphase spreads. M-FISH was performed as described (20).  
Human GCB cell culture  
Fresh, tonsil tissue was sourced from the Addenbrooke’s ENT Department, Cambridge with 
written informed consent of the patient/parent/guardian. Primary human GC B cells were 
isolated by MACS separation, cultured on CD40-L and IL-21 expressing YK-6 feeder cells 
and transduced as described before (21). Ethical approval for the use of human tissue was 
granted by the Health Research Authority Cambridgeshire Research Ethics Committee 
(REC no. 07/MRE05/44). At day 5 cells were transferred on CD40-L-/IL-21- feeder cells. 
Transduced (reporter+) cells were counted by FACS using counting beads on day 5 and 12 
post isolation.  
 
Table A 
 SOURCE Catalogue number Experiment 
Brilliant Violet 421™ anti-
mouse CD117 (c-Kit) Antibody  
BioLegend Cat#105828 FACS 
APC anti-mouse CD117 (c-kit) 
Antibody 
BioLegend Cat#135108 FACS 
Brilliant Violet 785™ anti-
mouse Ly-6A/E (Sca-1) 
Antibody  
BioLegend Cat#108139 FACS 
Biotin anti-mouse Ly-6G/Ly-6C 
(Gr-1) Antibody  
BioLegend Cat#108404 FACS 
Biotin anti-mouse NK-1.1 
Antibody  
BioLegend Cat#108704 FACS 
Biotin anti-mouse CD11c 
Antibody  
BioLegend Cat#117303 FACS 
Biotin anti-mouse/human 
CD11b Antibody 
BioLegend Cat#101203 FACS 
Biotin anti-mouse TER-
119/Erythroid Cells Antibody  
BioLegend Cat#116204 FACS 
Biotin anti-mouse CD3ε 
Antibody  
BioLegend Cat#100303 FACS 
BV785 anti-mouse B220 
(Clone RA3-6B2) 
BioLegend Cat#103245 FACS 
BV605 anti-mouse CD19 
(Clone 6D5) 
BioLegend Cat#115539 FACS 
BV785 anti-mouse CD19 
(Clone 6D5) 
BioLegend Cat#115543 FACS 
APC anti-mouse CD38 Biolegend Cat#102711 FACS 
APC anti-mouse/human 
CD45R/B220 Antibody  
BioLegend Cat#103212 FACS/Histology 
Alexa Fluor® 647 Rat anti-
Mouse CD267 - 
Clone  8F10   (RUO)  
BD Cat#558453 FACS 
PE/Cy7 anti-mouse CD93 
(AA4.1, early B lineage), Rat 
IgG2b, kappa 
BioLegend Cat#136506 FACS 
APC anti-mouse CD93 (AA4.1, 




FITC Rat Anti-Mouse IgM  
Clone  II/41   (RUO)  
BD Cat#553437 FACS 
PE/Cy7 anti-mouse CD23, Rat 
IgG2a, kappa, Clone: B3B4  
BioLegend Cat#101614 FACS 
PerCP/Cy5.5 anti-mouse IgD, 
Rat IgG2a, kappa, Clone: 11-
26c.2a  
BioLegend Cat#405710 FACS 
IgM Monoclonal Antibody 
(II/41), APC,  
Ebioscience Cat#17-5790-82 FACS 
IgM Monoclonal Antibody 
(II/41), Biotin 
Ebioscience Cat#13 5790 81 FACS 
IgD Monoclonal Antibody (11-
26c (11-26)), Biotin 
Ebioscience Cat#13-5993-82 FACS 
Biotin Rat Anti-Mouse Ig, κ 
Light Chain  
Clone  187.1   (RUO)  
BD Cat#559750 FACS 
Biotin Rat Anti-Mouse Ig, λ1, 
λ2, & λ3 Light Chain  
Clone  R26-46   (RUO)  
BD Cat#553433 FACS 
Biotin Rat Anti-Mouse IgG1  
Clone  A85-1   (RUO)  
BD Cat#550331 FACS 
Biotin Rat Anti-Mouse 
IgG2a/2b  
Clone  R2-40   (RUO)  
BD Cat#553398 FACS 
Biotin Rat Anti-Mouse IgG2a  
Clone  R19-15   (RUO)  
BD Cat#553388 FACS 
Biotin anti-mouse IgG3, 
immunoglobulin G3 
BioLegend Cat#406803 FACS 
Biotin Rat Anti-Mouse IgE  
Clone  R35-118   (RUO)  
 
BD Cat#553419 FACS 







PE anti mouse CD138 
(Syndecan-1), 
Rat IgG2a, kappa, Clone: 281-
2   
BioLegend Cat#142504 FACS, histology 
APC anti-mouse CD138 
(Syndecan-1), Rat IgG2a, 
kappa, Clone: 281-2  
BioLegend Cat#142506 FACS 
PE/Cy7 anti-human CD2, 
Mouse IgG1, kappa, Clone: 
TS1/8  
BioLegend Cat# 309214 FACS 
APC anti-human CD2, Mouse 
IgG1, kappa, Clone: RPA-2.10  
BioLegend  Cat#300213 FACS, histology 
FITC anti-mouse CD21/CD35 
(CR2/CR1), Rat IgG2a, kappa, 



























MHC Class II (I-A/I-E) 
Monoclonal Antibody 












Human antibodies    
FITC anti-human CD19 
Antibody 
 
BioLegend Cat#302256 FACS 
APC anti-human HLA-DR, DP, 
DQ Antibody 
 
BioLegend Cat#61714 FACS 
PE anti-human CD54 Antibody 
 
BioLegend Cat#353106 FACS 
APC anti-human CD95 (Fas) 
Antibody 
 
BioLegend Cat#305612 FACS 
FITC anti-human CD23 
Antibody 
 
BioLegend Cat#338505 FACS 
APC anti-human CD3 Antibody 
BioLegend Cat#300311 FACS 
FITC anti-human CD20 
Antibody 
 
BioLegend Cat#302304 FACS 
APC/Cy7 anti-human Ig light 




PE anti-human Ig light chain 
lambda Antibody 
BioLegend Cat#316608 FACS 
TruStain FcX™ (anti-mouse 
CD16/32, clone 93) 
BioLegend Cat#101320 FACS 
Goat anti-MU Kappa (southern 
blot) 
Southern bio Cat#2050-01 elispot 
Goat anti-MU Lambda 
(southern blot) 
Southern bio Cat#1060-01 elispot 
Goat anti-MU Lambda Biotin 
(southern blot) 
Southern bio Cat#1060-08 elispot 
Goat anti-MU Kappa Biotin 
(southern blot) 
Southern bio Cat#1050-08 elispot 
Ha-Tag (C29F4) Rabbit mAb Cell signaling Cat#3724 P Western blot ,IP, 
histology 
c-Myc (D84C12) Rabbit mAb Cell signaling Cat#2278 S Western blot 
EBV LMP2A antibody [14B7] -  Abcam Cat#ab59026 Western blot 
MONOCLONAL ANTI-BETA 
ACTIN 
Sigma Cat#A2228-200UL Western blot 
XP RBPSUH (D10A4) XP 
Rabbit mAb 
Cell signaling Cat#5313 P Western blot 
Anti-LMP1 mouse hybridoma 
supernatant S12 
Elliott Kieff Harvard 
medical school 
 Western blot  
 






Cat#115-035-003 Western blot 




Cat#711-035-152 Western blot 




Cat#712-035-150 Western blot 
Goat Anti-Human IgD-BIOT Southern Bio Cat#2030-08   southern 
 
Table B 
Primers to amplify translocation sites in LMP1-Ls 
Chr11_Rnf145_r
v  CCAAGGCTCGTGGATATTGT  
Chr12_Igh_rv  GCTGACTCCTGGTTGCTAGG  
Chr11_Rel_rv  CGCAGGAATGTGAGGAATGT  
Chr6_Igk_rv  AACACTGGATAAAGCAGTTTATGCCCTTTC  
Rosa26_fw GGAGTGTTGCAATACCTTTCTGGGAGTTC Control site 
Rosa26_rv TGTCCCTCCAATTTTACACCTGTTCAATTC Control site 
Primers to amplify CAS9 cutting sites 
Cdkn2a 
cr1+2+3_fw GTCAGAAGCTTTTGGACCAACTA  
Cdkn2a 
cr1+2+3_rv CGTACATAGGGCTTCTTTCTTGG  
B220_fw CGGGAAGACTGTGAATAAGGAAC  
B220_rv CATTCCACGTCCTGTTGTTTAGA  
Cd44_fw AGTCTTCACTTACAAGCACTTCT  
Cd44_rv TTCAACTGTCAGGGAGGAGCCTTCCAG  
Bcl2L11cr1-2-
3_fw    CCTCCCTACAGACAGAACCG  
Bcl2L11cr1-2-
3_rv     GGCTTTAAATGCTCCCCACA  
VDJ-PCR-Primers 
JH intronic REV CTCCACCAGACCTCTCTAGACAGC  
VHA (J558/VH1)  ARGCCTGGGRCTTCAGTGAAG  
VHB (Q52/VH2) CTCACAGAGCCTGTCCATCAC  
VHC (36-60/VH3) TCTCAGWCTCTGTCYCTCACC  






(GAM3/VH9) GGAGAGACAGTCAAGATCTCC  
sgRNA sequences 
B220 CAGTGGTGCGAGCAGGTAAG  
Bcl2l11 #1 GTGCACTGAGATAGTGGTTGA  
Bcl2l11 #2 GTTGACTTGTCACAACTCAT  
Bcl2l11#3 GTACCCATTGCACTGAGATAG  
Mouse Anti-Human CD44-
BIOT 
Southern Bio Cat#9400-08  southern 
BCL6 Antibody Proteintech Cat#21187-1-AP histology 
IRF4/Mum1 antibody Proteintech Cat#11247-2-AP histology 
CD10 antibody St Johns laboratory Cat#STJ97788 histology 






Southern biotech Cat# 6160-02 histology 
Rat anti-Metallophilic 
Macroph.:Biotin, Clone MOMA 
1, Isotype IgG2a 
Dianova Cat#T-2021 histology 
Streptavidin, Rhodamine 
Red™-X conjugate  
Thermo-fisher Cat#S6366 histology 
Goat Anti-Rabbit IgG(H+L), 
Mouse/Human ads-FITC 
Southern biotech Cat#4050-02 histology 
Cd44 CTACGCAGGTGTATTCCATG  
Cdkn2a #1 CCCCACTACCTTCTCCCGCC  
Cdkn2a #2 GTCGTGCACCGGGCGGGAGA  
Cdkn2a #3 GCGGTGCAGATTCGAACTGCG  
LMP1 #1 T TAA TCT GGA TGT ATT ACC A  
LMP1 #2 C CAA AAC AGT AGC GCC AAG  
LMP1 #3 A ATC ATC GGT AGC TTG TTG  
unspecific* ACTCCAGTCTTTCTAGAAGA 
*recognizes sequence 





Arf-fw TGTTGAGGCTAGAGAGGATCTTG  
Arf-rv CTGCACCGTAGTTGAGCAGA  
Bcl2l11-fw GAGATACGGATTGCACAGGA  
Bcl2l11-rv TCAGCCTCGCGGTAATCATT  
Hprt-fw GTCATGCCGACCCGCAGTC  
Hprt-rev GTCCTGTCCATAATCAGTCCATGAGGAATAAAC  
Ink4A-fw CGACGGGCATAGCTTCAG  
Ink4A-rv GCTCTGCTCTTGGGATTGG  
Myc-fw GCCAGCCCTGAGCCCCTAGT  
Myc-rv AGCAAACCTCCGCACAGCCC  
Prdm1-fw CCAGGTCTGCCACAAGAGATT  
Prdm1-rv TCCGATGACTCATAGAGGCTG  




























Figure S1 Characterization of LMP1-Ls  
A Histological sections of primary LMP1-L 34 (representative of 13 analyzed tumors). Upper panel: 
representative Hämalaun (H/L) staining. Lower panel: immuno-histology staining. Tumor (T) outlines 
are indicated in green. Scale Bars indicate 300µm (upper panel) and 100µm (lower panel). B 
Representative FACS-analysis of surface markers of 2ryLMP1-L 34. Left panel: Expression of B cell 
marker (CD19) and LMP1 target gene (FAS) on LMP1+ (huCD2+) (red) and LMP1- (huCD2-) cells 
(grey). Right Panel: Ig-light and -heavy chain surface expression on CD19+ cells C Southern blot for 
VDJ-rearrangements in 2ryLMP1-Ls. As controls, C57BL/6 Embryonic Stem cells (ES-cells), CD43- 
C57BL/6 B cells, tpLMP1 B cells and a previously established LMP1-L cell line 1019 are presented. 
White arrow heads indicate clonal VDJ-arrangements D Full exome sequencing of sorted (huCD2+) 
2ryLMP1-Ls. Absolute number of exome mutations in LMP1-Ls with a read-frequency of more than 
35%  (considered as clonal) is presented. Other mutations include silent mutations, mutations in 
non-coding sequences and mutations in non-protein-coding transcripts. (all clonal mutations are 
listed in Table S2) E Array-CGH detecting copy number changes in 2ryLMP1-L. Arrows indicate 
shared copy number variations (CNVs) between tumors 37 and 43. (all CNVs are listed in table S3) 
F Detailed analysis of copy number changes in Chr11 and 12 in Array-CGH G Representative M-
 
FISH on LMP1-L cell lines 37 and 43 (M-FISH analysis is summarized in table S4) H PCR on gDNA 
of primary LMP1-Ls or germline (GL) gDNA. Amplicons are spanning predicted translocation sites 
in LMP1-Ls 31 (t11;6) and 43 (t11;12). (Ig translations predicted by exome sequencing are listed in 
table S5). PCR amplifying a Rosa26-fragment is presented as a loading control I Sanger sequencing 

































Figure S2 Characterization of LMP1/EBF1 and LMP1/c-Rel expressing B cells 
A VDJ-PCR on bulk populations of iLMP1 B cells 45 days post transduction with RVs encoding Ebf1-
ires-GFP or Rel-ires-GFP  (from Fig. 2B). JH1-4 indicate approximate sizes of amplicons involving 
respective JH segments. B-C Phenotyping of EBF1- and c-Rel-LCLs (4-5 month of culture).  B White 
light images of cultured cells. C FACS-analysis of common LCL surface molecules. Non-filled 
histograms depict respective unstained controls. Human LCLs 21, 23 and 12 are presented as 
controls. D VDJ-PCR on Ebf1- or Rel-transduced iLMP1 B cells expanding in RAG2KOcgKO mice 
transplanted with 3*105 reporter+ cells (from Fig. 2D). Analysis was performed on liver gDNA at 
disease onset. LMP1-L cell lines 37 and splenic CD43- C57BL/6 B cells serve controls for clonal and 









Figure S3 Characterization of EBF1 and c-Rel activity in LMP1 B cells 
A Representative immuno-histology on splenic sections of 2nd LMP1-Ls. Sections from spleens of 
C57BL/6 and tpLMP1 mice are shown as control. FAS serves as a surrogate marker for LMP1 
expression (huCD2 could not be detected in PFA-fixed sections). (tpLMP1 is representative for 3 
cases analyzed; LMP1-Ls 34 is representative for 6 Relhigh cases analyzed) B-D Further analysis of 
RNA-sequencing of LMP1-Ls and tpLMP1 B cells from (Fig. 1E) A Non-supervised clustering 
(Euclidean distance and average linkage) performed on VSD-normalized expression data of 
established LMP1/NF-kB target genes  in LMP1-Ls. B Z-score normalized expression of all 
LMP1/NF-kB target genes. Each dot represents expression level of 1 gene in 1 LMP1-L or tpLMP1 
B cell sample. C FPKM-normalized expression of LMP1/NF-kB target genes with significantly altered 
expression in Relhigh LMP1-Ls compared to Ebf1high LMP1-Ls and tpLMP1 B cells E-F CD43- Splenic 
B cells from C57BL/6 mice were stimulated with αCD40 (2µg/ml) and IL-4 (20ng/ml). At 24h cells 
were transduced with RVs encoding, Ebf1-ires-GFP or Rel-ires-GFP. At 48h cells were transferred 
to 40LB feeders in the presence of IL-21 (20ng/ml). E Representative FACS-blots and quantification 
showing the ratio of CD138+ over CD138- reporter+ cells on day 11 post stimulation; n=6. F 
Quantification of Elispot-assays for total (k/l)-antibody secreting cells in FACS-sorted reporter+ cells; 
n=6. Bars indicate median frequency G Further analysis of RV-transduced iLMP1 B cells 
transplanted into RAG2KOcgKO mice (from experiment 2 D-G). Representative FACS-blots and 
quantification of PB-differentiation are presented (day 18 n=6 (not shown in Figure 2); Ebf1 day 24-
31 n=5; Rel day 62 n=2). Unless noted data are presented as mean ± SD. Significance was 
calculated using a Student’s t-test, p value adjusted via Benjamini & Hochberg (A), student t-test 
(B,C), one-way Anova with P-value adjusted via Dunnett (G) or paired students t-test (F) (*p<0.05; 
**p<0.005; ***p< 0.0005; n.s. non-significant) 
 
 
Figure S4 Characterization of EBNA3A expression in mouse B cells 
A Immunofluorescence of sorted mCherry+ iLMP1 B cells transduced with RVs encoding mCherry 
or HA-tagged EBNA-ORFs on detecting the HA-TAG on day 4 post TAT-Cre B Targeting strategy 
for R26EBNA3Astopf and R26BFPstopf alleles. CAG: artificial promotor; neo: neomycin resistance 
gene; stop: transcriptional stop cassette; HA: Human influenza hemagglutinin-TAG; loxP: 
recombination site for Cre-recombinase; huCD2: cytoplasmic signaling domain deleted human CD2; 
ires: internal ribosome entry site. Restriction enzyme digest cutting sites and probes for southern 
blot are indicated. C Southern blot of indicated ES-cell clones, detecting on-target integration (R4A 
probe) and potential random integrations (neo-probe). Clone D4 was selected to create the 
R26EBNA3Astopf line. Clone 65 was selected to create the R26BFPstopf line D-I Analysis of Cd19-Cre 
R26EBNA3Astopf and Cd19-Cre;R26BFPstopf mice D Western Blot of whole cell lysate (WCL) or HA-
co-immunoprecipitation performed with lysates of αCD40 (2µg/ml) and IL-4 (20ng/ml) stimulated 
splenic B cells from indicated genotypes on day 4. (Representative of 2 experiments) E 
Quantifications showing spleen weight, total splenic cell number and total splenic B cell number 
(CD19+/B220+); spleen size n=15 (Cd19-Cre;R26BFPstopf), n=21 (Cd19-Cre;R26EBNA3Astopf); 
splenocytes: n=12 (Cd19-Cre;R26BFPstopf), n=18 (Cd19-Cre; R26EBNA3Astopf); B cells: n=9 (Cd19-
Cre R26BFPstopf), n=13 (Cd19-Cre R26EBNA3Astopf) F Representative FACS-analysis of  
 
BFP+/CD93-/CD19+/B220+ mature splenic B cells. Upper panels and quantification show frequency 
of CD23lowCD21+ marginal zone B cells (MZB), CD23+CD21low Follicular B cells (FOB) and 
CD23lowCD21low cells; n=5. Lower histograms depict IgM and IgD expression in indicated subgroups 
(representative of 5 biological replicates). Non-B cells are presented as low control G Immuno-
histology on splenic sections representative of 4 independent mice per group. Red dotted lines 
indicate the follicle-boarder (MOMA-1 staining). Fo (Follicle) MZ (Marginal zone) H-J Analysis of 
FACS-sorted reporter+ CD19+/CD23+ FOBs. H FOBs were stimulated in vitro with αCD40 (2µg/ml) 
and IL-4 (20ng/ml) for 2 days then transferred on 40LB feeder cells in the presence of IL-21 
(20ng/ml). Quantification shows CD138 expression among reporter+ cells on day 11 (aCD40/IL-4); 
n=11 (Cd19-Cre;R26BFPstopf), n=12 (Cd19-Cre;R26EBNA3Astopf). I In vitro growth curve of FACS-
sorted BFP+/CD19+/CD23+ FOBs stimulated with αCD40 (2µg/ml) and IL-4 (20ng/ml); n=8 (day 
0,1,2,3,4) n=6 (day5). J FOBs were stimulated with LPS (10µg/ml) and IL-4 (20ng/ml). Quantification 
shows CD138 expression among reporter+ cells on day 5; n=3. 
Data are presented as mean ± SD. Significance was calculated using a non-paired Student’s t-test 
(E,H,I,J) or two-way Anova with Sidak’s multiple comparisons test (F) (*p<0.05; **p<0.005; ***p< 



























Figure S5 Characterization of LMP1/EBNA3A B cells 
A RT-qPCR-based quantification of Arf-, Ink4a- and Bcl2l11-expression in iLMP1 and 
iLMP1/EBNA3A B cells day 6 post TAT-Cre. Expression is normalized to HPRT and the expression 
levels of CD43- naïve splenic B cells stimulated with αCD40 (2µg/ml) and IL-4 (20ng/ml) for 4 days. 
Fold change is indicated; n=8 (iLMP1;Arf); n=6 (iLMP1/EBNA3A;Arf); n=6 (Ink4a); n=5 (Bcl2l11) B 
Heatmap showing lg2-FPKM-normalized expression of indicated genes in RNA-sequencing from 
Fig. 5D C-D CD43- B cells from R26LMP1stopf/CAS9tg were treated with TAT-Cre (iLMP1/CAS9). 
iLMP1/CAS9 B cells were either transduced with RVs encoding mCherry, EBNA3A-ires-mCherry or 
sgRNAs targeting indicated genes (reported by mCherry or BFP). B220- and LMP1-guides were 
used as a non-selected and negatively selected knockout control, respectively C Quantification of 
reporter+ cell number day 8 over day 3 is presented. Cdkn2a-gRNAs target Ink4a- and Arf-ORF; n=5 
D KO-efficiency in sorted reporter+ cells on day 6 post TAT-Cre as estimated by ICE-analysis. E-F 
Analysis of tpLMP1 and tpLMP1/EBNA3A mice (from Fig. 5E) E Representative FACS-analysis and 
quantification of reporter+CD138+ PBs in spleens on day 35 p.t.; n=3 F VDJ-PCR on splenic cells at 
day 35 p.t.. CD43- splenic C57BL/6 B cells serve as a positive control for a polyclonal B cell 
population (representative of 3 biological replicates). G Reanalyzes of a CHIP-array from Morscio et 
al showing REL and EBF1 expression in human PT-ABC-DLBCL. Rows represent independent 
probes on the array. Data are presented as mean ± SD. Significance was calculated using a Man-
Whitney U test (A), one-way Anova with P-value adjusted via Dunnett (C) or Welch’s t-test (E) 







 Figure S6 Characterization of LMP1, LMP2A and EBNA3A co-expressing B cells 
A 3*106 B cells from Cg1-Cre R26LMP1stopf/R26LMP2Astopf were transferred into RAG2KO mice (see 
also Fig. 6A). Quantification shows absolute number of splenic huCD2+/GFP+ B cells (CD19+/CD138-
) or PCs (CD138+/CD19low) at indicated timepoints after reconstitution; n=3 (day7-8), n=4 (day16-
17/28) B CD19+CD138-huCD2+GFP- LMP1-Lymphoma arising in one mouse of (A) C Southern blot 
of indicated ES-cell clones, detecting on-target integration (R4A-probe) and additional random 
integrations (neo-probe). Clone 6 was selected to generate the R26LMP1_LMP2Astopf line. Targeting 
strategy for the R26LMP1_LMP2Astopf allele is indicated. neo: neomycin resistance gene; stop: 
transcriptional stop cassette; loxP: recombination site for Cre-recombinase; huCD2: cytoplasmic 
signaling domain deleted human CD2; ires: internal ribosome entry site D Western blot of whole cell 
lysates from iLMP1_LMP2A and iLMP1/LMP2A B cells day 4 post TAT-Cre. Wild type B cells 
stimulated for 4 days with αCD40 (2µg/ml) and IL-4 (20ng/ml) serve a negative control for LMP1 and 
LMP2A expression. (representative of 2 experiments) E Representative FACS-analysis of 
iLMP1_LMP2A and iLMP1/LMP2A B for expression of LMP1-target gene FAS on day 3 post TAT-
Cre (representative of 2 biological replicates). iLMP2A B cells are presented as a low control F RT-
qPCR-based quantification of Prdm1-expression in sorted reporter+ cells day 6 post TAT-Cre. 
Expression was normalized to HPRT and CD43- splenic C57BL/6 B cells stimulated with αCD40 
(2µg/ml) and IL-4 (20ng/ml) for 4 days. n=7 (CD40/IL-4); n=10 (iLMP1 and iLMP1_2A/EBNA3A), n=8 
(iLMP1/EBNA3A and iLMP1_2A) G Elispot for total (k/l) antibody secreting cells on sorted reporter+ 
cells day 9 post TAT-Cre treatment or non-stimulated CD43- splenic C57BL/6 B cells taken ex vivo. 
Quantification and images of representative images of wells with 93 cells are presented; n=3 (B 
cells), n=4 (iLMP1 and iLMP1_2A) H Growth curve of bulk cultures; n=3 I FACS-analysis for PC 
marker expression on iLMP2A B cells on day 6 post TAT-Cre (Representative of 2 biological 
replicates) J-K iLMP1_LMP2A and iLMP1_LMP2A/EBNA3A B cells were transduced with RVs 
encoding GFP or Prdm1-ires-GFP and analyzed on day 9 post TAT-Cre J FACS-based 
 
quantification of CD138+/B220low plasma cells; n=7 K Elispot for total (k/l)-antibody secreting cells 
in FACS-sorted reporter+ iLMP1_LMP2A and iLMP1_LMP2A/EBNA3A B cells transduced with RVs 
encoding GFP or Prdm1-ires-GFP. Quantification and representative images of wells with 120 cells 
are presented. n=5 (LMP1_2A), n=6 (LMP1_2A/EBNA3A) L Quantification of CD138+/B220low 
plasma cells among reporter+ LMP1_2A B cells transduced with RVs encoding mCherry, GFP or HA-
tagged EBNA genes (reported by ires-mCherry or GFP) on day 9 post TAT-Cre; n=8 M 
Representative FACS-analysis of CD138 and CD19 expression on huCD2+ cells in spleens of 
tpLMP1_2A mice at disease onset N Quantification of (m); n=4 O Quantification of spleen size in 
tpLMP1_2A and tpLMP1_2A/EBNA3A mice at disease onset; n=3 (RAG2KOcgKO),n=4 (tpLMP1_2A), 
n=8 (tpLMP1/EBNA3A) P Growth curve of bulk culture; n=6 (iLMP1/LMP2A), n=3 
(iLMP1_LMP2A/EBNA3A). Q FACS-based quantification of active caspase 3; n=6 (LMP1_2A day4), 
n=3 (LMP1_2A/EBNA3A day4), n=9 (LMP1_2A day6), n=9 (LMP1_2A/EBNA3A day6), n=6 
(LMP1_2A day8), n=6 (LMP1_2A/EBNA3A day8). Data are presented as mean ± SD. Significance 
was calculated using a Welch’s t-test (A, H), Man-Whitney U test (G), one-way Anova with P-value 
adjusted via Dunnett (F) non-paired Student’s t-test (N,O,Q) or a paired Student’s t-test (J, K, L) 












Figure S7 The role of Myc in LMP1, LMP2A and EBNA3A co-expressing B cells 
iLMP1/LMP2A and iLMP1_LMP2A/EBNA3A B cells transduced with RVs encoding GFP or Myc-ires-
mCherry A Representative FACS-analysis and quantification of sorted reporter+ cells in S/G2/M 
phase on day 6; n=8 B FACS-based quantification of CD138+B220low PCs on day 9; n=3. C 
Quantification of Elispot-assays for total (k/l)-antibody secreting cells in FACS-sorted reporter+ cells 
on day 9; n=5 (iLMP1_2A) n=6 (iLMP1_2A/EBNA3A). D VDJ-PCR of two lymphomas arising in 
RAG2KOcgKO mice transferred with 5*106 Myc-transduced iLMP1_2A/EBNA3A B cells on day 3 after 
TAT-Cre (from Fig. 7G). CD43- splenic B cells of C57BL/6 mice were used as a positive control for 
a polyclonal B cell population. Data are presented as mean ± SD. Significance was calculated using 
a paired Student’s t-test (A), Student’s t-test (B) or Welch’s test (C) (*p<0.05; **p<0.005; ***p< 
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